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Life cycle assessment 
A B S T R A C T   
Aerogels are the lightest processed solid materials on Earth and with the largest empty volume fraction in their 
structure. Composition versatility, modularity, and feasibility of industrial scale manufacturing are behind the 
fast emergence of aerogels in the drug delivery field. Compared to other 3D materials, the high porosity 
(interconnected mesopores) and high specific surface area of aerogels may allow faster loading of small-molecule 
drugs, less constrained access to inner regions of the matrix, and more efficient interactions of the biological 
milieu with the polymer matrix. Processing in supercritical CO2 medium for both aerogel production (drying) 
and drug loading (impregnation) has remarkable advantages such as absence of an oxidizing environment, clean 
manufacture, and easiness for the scale-up under good manufacturing practices. The aerogel solid skeleton 
dictates the chemical affinity to the different drugs, which in turn determines the loading efficiency and the 
release pattern. Aerogels can be used to increase the solubility of BCS Class II and IV drugs because the drug can 
be deposited in amorphous state onto the large surface area of the skeleton, which facilitates a rapid contact with 
the body fluids, dissolution, and release. Conversely, tuning the aerogel structure by functionalization with drug- 
binding moieties or stimuli-responsive components, application of coatings and incorporation of drug-loaded 
aerogels into other matrices may enable site-specific, stimuli-responsive, or prolonged drug release. The pre-
sent review deals with last decade advances in aerogels for drug delivery. An special focus is paid first on the 
loading efficiency of active ingredients and release kinetics under biorelevant conditions. Subsequent sections 
deal with aerogels intended to address specific therapeutic demands. In addition to oral delivery, the physical 
properties of the aerogels appear to be very advantageous for mucosal administration routes, such as pulmonary, 
nasal, or transdermal. A specific section devoted to recent achievements in gene therapy and theranostics is also 
included. In the last section, scale up strategies and life cycle assessment are comprehensively addressed.   
1. Introduction 
Processing of advanced materials as aerogels has opened new ways of 
addressing a variety of technological challenges while fulfilling eco- 
friendly criteria. Aerogels are mainly featured by their physical struc-
ture: solid with extremely low density (0.0001 to 0.2 g/cm3), porosity 
larger than 90% with predominance of open pores in the mesoscale 
(2–50 nm), and high specific surface area (>200 m2/g) [1,2]. Therefore, 
aerogels are the lightest processed solid materials on Earth with the 
largest empty volume fraction in their structure. Empty space filled with 
air or other gases notably contributes, for example, to the outstanding 
insulation capability of aerogel materials, offering novel strategies to 
achieve requirements of low weight and minimal waste of space of 
modern energy storage and transfer in industrial installations, buildings, 
and transport vehicles [3]. Aerogels also show outstanding capabilities 
for sorption of metals, solvents, fuel and oil spills as well as gases, being 
useful in selective captures for catalysis and analytical purposes and 
remediation [4–6]. In parallel, the versatility of the materials that can be 
used (e.g., ceramics, metals, polymers and hybrids), the mild conditions 
required for processing, and the variety of obtainable shapes are very 
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appealing to explore applications in the biomedical field [7,8]. In 
addition, the use of advanced fabrication methods such as additive 
manufacturing in the processing of aerogels enhances their favorable 
properties even more [9,10]. Silica-based aerogels are the most widely 
investigated aerogels, but the field of biopolymer (polysaccharide, 
protein, nucleic acid) aerogels is rapidly growing for both biomedical 
and non-biomedical applications demanding improved mechanical 
properties, sustainability, biocompatibility and biodegradability 
[11–13]. 
By definition, an aerogel is generated by the replacement of the 
liquid inside a gel with a gas [14]. Similar to the hydrogels widely used 
in biomedicine, aerogels are also formed by 3D networks of organic 
polymers, inorganic materials or composites assembled colloidal mate-
rials. The main difference relies in the extraordinary greater degree of 
swelling of the dried network of aerogels. Such an expanded structure is 
made permanent by stretching the chains or the self-assembled com-
ponents to levels that are hardly obtained yet by immersion in common 
solvents followed by conventional solvent evaporation techniques. 
Freeze-drying is intended to keep the original swelling achieved by the 
hydrogel in a favorable aqueous medium through rapid freezing of water 
inside the pores followed by sublimation under low pressure conditions. 
Nevertheless, the liquid-gas surface tension and liquid-solid adhesive 
forces may lead to the shrinking of the pores and promote further solid- 
solid interactions. Expansion of water during freezing may also damage 
the structure. Cosolvents that reduce surface tension (e.g., tert-butyl 
alcohol) or the use of cryoprotectants (e.g. trehalose combined with 
polyethylene glycol, PEG) can attenuate some of these drawbacks [15]. 
Differently, production of aerogels applying supercritical processing 
involves several changes of the liquid phase with organic solvents and 
subsequent extraction/drying under supercritical conditions (commonly 
in the presence of supercritical CO2; scCO2). This processing avoids the 
liquid-gas surface tension and liquid-solid adhesive forces and, there-
fore, prevents the collapse of the original pores [16]. The supercritical 
drying technology is compatible with a variety of solvents and even 
enables the use of poorly-water soluble materials that are not suitable as 
hydrogel components. Detailed comparative analysis of freeze-drying 
and supercritical drying processes and their respective outcomes can 
be found in recent reports [2,11]. The advent of non-supercritical drying 
techniques may further expand the aerogels field in a near future. 
A priori, homogeneous structure, tunable mesh size, interconnected 
pores, and increased surface area appear as advantageous features for 
exploring the capabilities of aerogels as drug delivery systems. 
Compared to common pharmaceutical hydrogels and their freeze-dried 
spongy cryogels, aerogels may allow faster loading of small-molecules, 
less constrained access to inner regions of the matrix, and more effi-
cient interactions with the polymer matrix. The aerogel solid skeleton 
dictates the chemical affinity of the matrix to the adsorbed molecule 
and, in the case of drugs, their partition coefficient between the aerogel 
and the aqueous medium when immersed in body fluids. However, some 
concerns on the use of aerogels as drug delivery platforms may also 
raise. The predominance of mesopores and the absence of larger pores in 
conventional aerogels may result in size exclusion effects that hinder the 
uptake of bulky molecules and therapeutic macromolecules in the aer-
ogel network, compared to sponges or particles endowed with hierar-
chical porosity [17]. Moreover, wetting in aqueous fluids may trigger 
the collapse of the forcedly stretched chains to a more thermodynami-
cally stable conformation or even the dissolution if the chains are not 
chemically crosslinked. Therefore, drug loading into preformed aerogels 
is so far mostly carried out in scCO2 medium (as explained in more detail 
in the next section). The critical point of CO2 (31.1 ◦C, 7.4 MPa) is 
compatible with the stability range of most drugs and proteins. Drug 
solubility in scCO2 can be enhanced either by increasing the pressure or 
by adding cosolvents and, after processing, CO2 evaporates and no traces 
of solvent remain in the aerogel. The absence of oxygen, the feasibility of 
carrying out the drug loading under clean conditions, and the easiness 
for the scale-up and production under good manufacturing practices 
(GMP) are remarkable advantages from the perspective of 
manufacturing of pharmaceutical grade products [18,19]. 
Another limitation is that once the drug-loaded aerogel is adminis-
tered to the body, the large surface contact area with the physiological 
media may lead to fast and uncontrolled drug release, especially if the 
solubility and partition coefficient of the drug into the body fluids are 
high [11]. Nevertheless, regulation of the components solubility, degree 
of crosslinking, functionalization and interactions with the drug, as well 
as specific coatings and incorporation of aerogels in other matrices could 
be implemented to fine-tune the capability of aerogels to perform as 
platforms for controlled drug release or, oppositely, may further pro-
mote their role as fast dissolving solubility enhancers [20–23]. 
Some physical properties of the aerogels appear to be very advan-
tageous for drug delivery through a variety of parenteral and, especially, 
mucosal administration routes [14]. The high capability of aerogels to 
absorb liquids may facilitate a precise regulation of the sorption of ex-
udates from skin wounds and preserve moisture levels that promote 
wound healing, while the aerogel still regulates drug release [24]. 
Enhanced drug solubility and improved dissolution rate have been 
shown to promote drug penetration through the dermis [25], and 
therefore aerogels may be useful for transdermal treatments. Also, the 
low apparent density of aerogels makes them particularly appealing for 
pulmonary administration both for local treatment of lung diseases and 
for the systemic delivery (transpulmonary) of labile biopharmaceuticals, 
including those for gene therapy and vaccination [26–28]. Moreover, 
selective nasal administration may be feasible by regulating the particle 
size and adhesion properties [29]. 
Owing to their great versatility, modularity, and feasibility of 
manufacturing in an industrial scale, aerogels have emerged as one of 
the most exciting and promising platforms for drug delivery. In the last 
decade, there has been a growing interest in exploring the performances 
of aerogels in drug formulation as reflected in the increasing number of 
publications collected in the Web of Science database for the search 
criteria “aerogel AND drug delivery” (Fig. 1). There are also several 
other potential applications of aerogels in biomedicine, such as regen-
erative medicine, bioimaging and biosensors, which have been covered 
elsewhere [30–33]. 
This review deals with the peculiarities of aerogels as drug carriers 
and critically discusses their current and future contribution to the field 
of advanced drug delivery. Previous reviews on aerogels and drug de-
livery have mainly focused on the aerogel perspective and classified the 
information attending to the aerogel composition (inorganic/organic) 
and preparation protocols [34–36]. The field is evolving very rapidly 
(ca. 200 papers in the last 5 years), and recent reports have provided 
relevant information not only on characterization of textural properties 
Fig. 1. Number of publications in Web of Science Core Collection database for 
the search criteria “aerogel AND drug delivery” (search date: December 
18, 2020). 
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and drug loading and release tests in vitro, but also on in vivo proof-of- 
concepts for addressing specific therapeutic demands. Therefore, the 
present work firstly focuses in Section 2 on the advances made over last 
decade and that were devoted to understand how aerogels can fulfil the 
demands of drug formulations in terms of drug loading content, solu-
bilization, physicochemical stability, and drug release kinetics and tar-
geting. Following sections (Sections 3 to 5) gather the information from 
the perspective of feasible administration routes for drug-loaded aero-
gels to address specific therapeutic demands. Special focus is paid first 
on the loading efficiency of active ingredients and release kinetics under 
biorelevant conditions. Also, novel formats such as 3D printed aerogels 
and their potential are analyzed [10,26,37]. Finally, engineering-based 
scale up strategies and life cycle assessment are addressed in the last 
section of this review. 
2. Drug loading into and release from aerogels: mechanisms and 
variables 
2.1. Drug loading modalities and outcomes 
Several protocols to integrate drugs during the fabrication process or 
once the aerogels are formed have been explored [38]. The four main 
strategies for the loading of drugs into aerogels (Fig. 2) are explained 
below.  
(a) The first strategy, and apparently the simplest one, consists in 
adding the drug to the precursor solution of the gel (e.g., polymer 
dispersion). This approach uses drugs that are stable under the 
gelling conditions and poorly soluble both in the organic solvents 
used for solvent exchange and in the supercritical fluid used for 
drying to avoid premature drug extraction [35]. An excellent 
example is nicotinic acid; its solubility is 1.67 g/100 mL water, 
0.7 g/100 mL ethanol and 1.84⋅10− 4 g/100 mL scCO2 (35 ◦C, 100 
bar). Therefore, alginate aerogels loaded with nicotinic acid can 
be prepared by adding the drug to the alginate aqueous solution 
before gel crosslinking, exchange of water with ethanol, and 
scCO2 drying [39]. Interestingly, the presence of the drug notably 
attenuated the shrinkage of the alginate hydrogels in ethanol, 
favoring the production of aerogels with higher surface areas. 
Drugs that are soluble in water, organic solvents and scCO2 may 
require processing by freeze-drying instead of scCO2 drying [40] 
or by impregnation using supercritical fluids (as described below 
in strategy d).  
(b) Alternatively, for drugs that are soluble in alcohols but not in 
scCO2, the gel can be prepared first and then soaked into the drug 
solution for loading. Subsequent supercritical drying leads to 
drug precipitation inside the aerogel pores as the solvent is being 
removed [41]. This process resembles a gas antisolvent crystal-
lization [32] and, differently to the other strategies, the outcome 
is the high loading of the drug in the crystalline state. Since the 
drug solubility in water is low, the release is mainly governed by 
drug dissolution and favored by the increased surface area pro-
vided by the aerogel matrix. However, the drug loading process 
could be slow (especially in the inner pores) and incomplete, as 
observed with silica aerogels exposed to paracetamol solutions. 
Drug diffusion from the outer concentrated medium to the inner 
pores of silica requires quite a long time. Therefore, in the typical 
timeframe of the preparation protocol, a gradient of adsorbed 
drug is generated from the outer layers of the aerogel (more 
concentrated) to the inner regions (less concentrated). This is 
particularly evident when low drug concentrations are used, the 
soaking time in the drug solution is short, and the exchange of the 
solvent by scCO2 occurs slowly and some drug molecules can 
even move from inside to the surface [41]. Even if showing some 
drawbacks, this technique allows for reproducible drug 
Fig. 2. Strategies to load drugs into aerogels: (a) the drug is added to the precursors solution; (b) the drug is added to the gel; (c) the drug is incorporated during the 
supercritical drying; and (d) the aerogel is formed first and then the drug is loaded. 
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crystallization in aerogels both in terms of drug loading and ob-
tained polymorph.  
(c) Drugs sensitive to common solvents but soluble in scCO2 (e.g., 
acetylsalicylic acid or essential oils) can be loaded during aerogel 
formation in the supercritical drying step [42,43]. Improved 
knowledge on drug adsorption isotherms under supercritical 
conditions allows predicting the kinetics of the loading and the 
saturation values, as explained below [44,45].  
(d) Formulation of drugs into preformed aerogels involves the 
exposure of the aerogel to liquid or gas phases containing the 
drug, which must diffuse through the pore network [34,46]. 
Immersion in aqueous or organic solvents may trigger aerogel 
deswelling or partial dissolution depending on the skeleton 
composition and also requires an additional step of solvent 
removal, with the risk of pore collapse and remaining of solvent 
traces that may lead to drug instability or toxicity. These draw-
backs of extra processing steps together with the risk of losing the 
unique properties of the aerogel support the use of scCO2 for the 
drug loading of preformed aerogels in case of drugs that dissolve 
in this solvent. Compared to other supercritical fluids, CO2 is 
regarded as safe by the regulatory agencies for the processing of 
pharmaceutical and food products [47]. As advantageous fea-
tures, CO2 itself has low toxicity and low density, is noncom-
bustible and can be recycled, and the supercritical conditions are 
achieved at mild values of pressure (7.4 MPa) and temperature 
(31.1 ◦C), which makes the process more economically conve-
nient than other supercritical fluids [48]. Particularly, the pro-
cessing temperature under scCO2 medium can be close to that of 
human body, which may prevent the thermal degradation of 
temperature-sensitive therapeutic substances. For comparison, 
the critical point of water is 373.9 ◦C and 22.1 MPa [49]. Indeed, 
a large variety of hydrophilic and lipophilic drugs have been 
shown to withstand the processing under scCO2 conditions [50]. 
scCO2 is a non-polar solvent with low dielectric constant and, 
therefore, it cannot solubilize polar drugs and therapeutic pro-
teins. Nevertheless, since scCO2 can establish a variety of in-
teractions with solutes, such as acid/base, dispersion, induced 
dipole, and quadrupole interactions, it becomes a suitable solvent 
for mid-polarity substances if the required concentration is rela-
tively low [51,52]. Drug solubility can be enhanced either by 
increasing the pressure or by adding cosolvents (acetone, meth-
anol, or ethanol). After processing, CO2 evaporates fast, and no 
solvent traces remain in the aerogel. Preparation of water-in-CO2 
and oil-in-CO2 emulsions has also been investigated to enhance 
the drug concentration using adequate surfactants and lipids 
[48]. Moreover, aerogel formation (scCO2 drying) and subse-
quent drug impregnation can be integrated into a one-pot process 
[42]. 
The process of aerogel impregnation with drugs using supercritical 
fluids is known as adsorption precipitation [53]. A common protocol 
may be described as follows: (i) the aerogel monolith or particles 
(wrapped in a porous mesh) and the drug particles (directly or inside a 
permeable container) are placed together in a temperature-controlled 
pressurizable chamber; (ii) CO2, solely or doped with cosolvents, is 
introduced in the chamber and the supercritical conditions are achieved; 
(iii) the drug is dissolved in the supercritical fluid and the penetration of 
scCO2 into the aerogel pores facilitates drug diffusion; (iv) the drug is 
adsorbed on the interior surface of the aerogel (skeleton) and an 
adsorption equilibrium is reached if sufficient time is given (if desired), 
and (iv) after a given time of exposition under static or agitated condi-
tions, the chamber is depressurized to remove CO2 and any other sol-
vent. Depending on whether the depressurization is slow or fast, the 
amount of drug adsorbed (deposited) on the aerogel may change. Slow 
depressurization (i.e., slow expansion) causes the precipitation of the 
drug that accessed the inner pores and was adsorbed onto their walls. 
The remaining drug that did not undergo adsorption may be dragged 
with the CO2 or deposited on the chamber walls. Conversely, fast 
depressurization (i.e., rapid expansion) may cause a sudden decrease in 
the drug solubility as the solvent evaporates, which may promote 
enhanced deposition of drug particles onto the external layers of the 
aerogel. Depending on whether the drug molecules have sufficiently 
high affinity for the aerogel skeleton or the drug concentration in the 
medium is still very high, drug adsorption or precipitation pre-
dominates, respectively [53]. Readers interested in the advantages of 
using scCO2 for the preparation of drug nanoparticles and nanocrystals 
are referred to a specialized review [51]. 
The knowledge of the mechanisms involved in the adsorption pre-
cipitation is crucial for tuning the rate, the amount and the crystalline 
state of the drug deposited into the aerogels. Non-swellable aerogels 
have extensively been studied in this regard [53]. In the sequence of 
pressurization-adsorption equilibrium-depressurization, the time to 
adsorption equilibrium is the rate-limiting step. Drug dissolution usually 
occurs in a few minutes, but diffusion through the supercritical fluid and 
into the aerogel and adsorption onto the skeleton may require between 
10 and 24 h to reach equilibrium [54]. Diffusion coefficients for drugs 
that fulfil the rule of five set by Lipinski for molecules showing good oral 
adsorption [55] are in the 10− 9–10− 8 m2/s range [56]. The diffusion 
coefficient increases as the molecular weight of the drug decreases or a 
combined increase in temperature and decrease in pressure occurs. 
Regarding the amount of drug that can be adsorbed, common values 
range between 0.1 and 0.8 g/g [53], although remarkably larger 
amounts have been reported for eugenol (up to 8 g/g) in rice husk ash 
silica aerogel [57]. Drug solubility in the supercritical fluid is not the 
main factor regulating drug adsorption and indeed the amount loaded 
cannot be predicted from its solubility. Differently, the strength of the 
drug-skeleton interactions and even the drug-drug interactions may 
determine both the adsorption at equilibrium and the physical state of 
the deposited drug particles. As a rule of thumb, an increase in drug- 
skeleton affinity and a decrease in drug intermolecular interactions 
favor the deposition of amorphous drug in the pore walls. Also, the 
aerogel density has been suggested to play a key role in drug adsorption, 
although some contradictory results have been reported [58,59]. 
The information available also calls the attention on the challenges 
to characterize the nanocrystals confined within pores smaller than 1 
μm, since they can become imperceptible using powder X-ray diffraction 
(XRD) techniques. Advantageously, the predominance of mesopores 
(2–50 nm) in the aerogel structure contributes to hinder the growth of 
the drug particles and minimizes the risk of drug crystallization, 
contributing to the stability of the amorphous particles or preventing 
crystal growth or polymorphic changes of drug nanocrystals. 
Overall, the strengthening of the drug-skeleton interactions has also 
two direct positive consequences: (i) higher drug amounts can be 
loaded, and (ii) the likelihood that the drug remains in the amorphous 
state increases. In addition, the affinity of the drug for the aerogel 
skeleton can be enhanced through its functionalization with oppositely 
charged groups; namely acidic functionalities to load basic drugs, or 
amino and hydroxyl moieties to load acidic drugs. As an example, 
functionalization of silica aerogels with amine groups (gas phase func-
tionalization) did not alter the density and porosity of the aerogel 
(surface area ~1000 m2/g; 0.14 g/cm3), but notably improved the 
adsorptive interactions with ketoprofen [60]. An increase in the content 
in amine groups from 1.06 to 2.98 wt% increased ketoprofen loading 
from 9.7 to 21.1 wt% due to specific interactions with the carboxylic 
acid group of the drug. The drug adsorbed did not show crystalline peaks 
and the release from the aerogels was faster than the dissolution rate of 
non-processed crystalline drug owing to its amorphization. Interest-
ingly, a retarding effect of the amine group-drug interactions on drug 
release rate was not observed; on the contrary, the most functionalized 
aerogels led to even faster release rate. More recently, the molecular 
imprinting strategy has been also explored to increase the loading of 
drugs into aerogels through ad-hoc arrangement of the binding sites 
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[61]. 
2.2. Drug release mechanisms 
Understanding drug release mechanisms is important to modulate 
the characteristics of the carriers and facilitate the design of new devices 
with advanced functionalities. General considerations can be formulated 
when the drug is physically deposited in mesoporous aerogels, but 
stimuli responsive systems where the active ingredient is chemically 
conjugated to the backbone have to be evaluated individually. This 
section deals only with the former systems. When the drug is dispersed 
on the surface and inside the pores of aerogel particles, drug release can 
be divided into two main mechanistic steps. The first step is the disso-
lution of the drug, which is followed by its transport from the device to 
the dissolution medium. Both processes are governed by several physi-
cochemical factors that determine the limiting step in the mechanism, 
and eventually the rate of drug release. The most relevant factors are the 
following [62]: i) Hydration characteristics of the deposited drug and 
the carrier matrix, including erosion and swelling; ii) Specific in-
teractions between the aerogel backbone and drug molecules; and iii) 
Mass transport processes effective in the hydrated delivery device. These 
factors have profound effects on both drug dissolution and transport, 
which should carefully be assessed in order to get a comprehensive 
understanding on drug release mechanism [63,64]. 
2.2.1. Hydration features 
When the drug delivery device gets in contact with body fluids, the 
aerogel particles are hydrated starting on the surface and gradually 
penetrating into the pore network. Consequently, the deposited solid 
drug is also hydrated, which leads to its dissolution; first on the outer 
surface of the aerogel and afterwards inside the pores. The hydrophi-
licity of the drug and that of the aerogel carrier can be significantly 
different, taking into account that the characteristics of the drug 
significantly depend on its crystallinity as well. When a hydrophilic drug 
is loaded into a hydrophilic aerogel, hydration and drug dissolution are 
often fast, and the rate determining step in drug release is the mass 
transport of the dissolved drug from the outer surface and pores towards 
the release medium. On the other hand, the dissolution of hydrophobic 
active ingredients is usually slow even in their amorphous forms. 
Aerogels are considered as highly hydrophilic if the backbone 
spontaneously absorbs water and develops a thick hydration layer, 
disregarding the solubility of the aerogel in water. Thus, in the case of 
highly hydrophilic aerogel carriers (e.g., polysaccharides, proteins, sil-
ica, and alumina), the facile hydration of the backbone effectively drives 
the displacement of the deposited drug, which considerably increases 
dissolution rate. In the same line of thoughts, when the aerogel carrier is 
hydrophobic (e.g. hydrophobized silica or biopolymers), its hydration is 
hindered, which usually results in the retarded release of active 
ingredients. 
Besides facilitating drug desorption, the facile hydration of hydro-
philic aerogels can lead to erosion, swelling, and in some cases, disso-
lution of the carrier matrix. Inorganic oxide (e.g., silica, alumina, 
titania) and crosslinked (bio)polymer aerogels are usually very hydro-
philic, but they do not swell upon hydration and their open mesoporous 
structure remains intact in water [65]. Mass transport into and out of 
these hydrated aerogel particles is practically unhindered due to the 
conserved highly interconnected open porous system. Another effect to 
be considered is that inorganic oxide aerogels tend to erode spontane-
ously in water yielding microparticles of 10–40 μm. Matrix erosion of 
the wet aerogel can be complete in 1–30 min in a stirred vessel. The fast 
erosion of bulk aerogels to microparticles with open pores usually results 
in the rapid release of loaded drugs. This is effective in most of the 
inorganic oxide based aerogel carriers. The erosion of hydrophobized 
aerogels in an aqueous milieu is slower. 
Differently, biopolymer aerogels undergo extensive structural 
changes upon wetting and hydration. When completely hydrated, 
carbohydrate and protein aerogels tend to swell due to the rearrange-
ment of the backbone, which finally results in the collapse of the pores 
and the formation of a hydrogel-like matrix. Because the collapse of the 
pore system is often fast, the swollen particles can entrap much of the 
loaded drug. In these cases, hindered diffusion from the hydrogel-like 
particles controls the rate of drug release. In extreme cases, the rate 
limiting process is the dissolution of the hydrated carrier matrix. These 
effects usually result in retarded drug release from biopolymer aerogels 
that swell in aqueous media. In sum, if hydrogel formation is fast, the 
loaded drug will be trapped in the hydrogel. If hydrogel formation is 
slow, the drug may dissolve and leave the porous structure before the 
collapse of the pores (and the formation of a hydrogel layer). 
It is important to emphasize that the dissolution of drugs and the 
hydration of aerogels, including erosion and/or swelling, depend on the 
chemical properties of the release medium. The most important prop-
erties are pH, temperature, ionic strength and the presence of surfac-
tants. A high variation in swelling or solubility can be utilized for 
developing stimuli responsive carriers. For example, chitosan and poly 
(N-isopropyl acrylamide) (PNIPAM) show, respectively, significant 
pH- and temperature-dependent swelling and aggregation [66,67]. In 
general, drug release is faster under such conditions where the pores of 
the carrier matrix remain open, and release is retarded when the pores 
collapse due to swelling. In addition, drug release is faster when the 
conditions favor the dissolution of the carrier. Details on stimuli 
responsive aerogel carriers are given later in Section 3.2. 
The different hydration characteristics of inorganic and biopolymer 
aerogels can be combined and utilized to tune drug release rate. One 
strategy is coating the porous carrier with biopolymer layers that swell. 
In these systems, hindered mass transport through the outermost hy-
drated biopolymer layer, and in the later stages, the dissolution of the 
layer determine the rate of drug release. It has been shown that the 
release of deposited curcumin is fast from pectin aerogel carrier. How-
ever, prolonged drug release was achieved by coating the loaded pectin 
aerogel with chitosan. A compact hydrogel layer forms from chitosan in 
water, which limits the transport of the dissolved drug into the release 
medium [68]. The feasibility of encapsulating silica aerogel with a 
tunable alginate aerogel layer has been explored too [22]. Additional 
examples for coated and core-shell aerogels are given later in Section 
3.3. 
Another strategy for controlled release is fusing the different hy-
dration properties of inorganic and organic materials by hybridization. 
A variety of silica-casein and silica-gelatin aerogels has recently been 
prepared utilizing co-gelation as part of the sol-gel method in synthe-
sizing the gel network of the aerogels. These hybrids are homogeneous 
on the nanoscale. Interestingly, silica-casein aerogels do not swell, and 
retain their open porous structures in water [69]. Silica-gelatin hybrid 
aerogels of low (<5 wt%) gelatin content do not significantly swell upon 
hydration, but the facile hydration of the backbone drives the rapid 
displacement of loaded hydrophobic drugs (e.g. ibuprofen and keto-
profen). Therefore, rapid release is characteristic for low gelatin content 
hybrids [70]. On the other hand, silica-gelatin aerogels of high (>20 wt 
%) gelatin content significantly swell in water, which results in the 
entrapment of loaded drugs and retarded drug release. Owing to these 
effects, drug release rate can be tuned by changing the ratio of the 
inorganic and organic components of the hybrid aerogel carrier, as seen 
in Fig. 3 [71]. The most studied strategies for controlling the hydration 
of aerogels is hydrophobization and crosslinking. In general, hydro-
phobization slows down the wetting of the aerogel matrix, and its 
limited hydration prevents erosion. Controlled hydrophobization has 
been explored in tuning the release properties of silica, inorganic- 
organic hybrid and biopolymer aerogels [72–74]. 
2.2.2. Specific interactions 
Every interaction between the aerogel backbone and the drug 
molecule is considered specific besides dispersion forces and dipole- 
dipole interactions. The most common interactions are hydrogen 
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bonding and ionic bonding, but coordination bonds (e.g. with metal ion 
containing drugs) and supramolecular interactions are possible as well. 
The nature of specific interactions heavily depends on the chemical 
structure and physical states of the drug and the aerogel. The physical 
state, e.g. the crystallinity of the components, is determined by the 
conditions of aerogel synthesis and drug deposition. When the carrier 
device becomes hydrated, the chemical conditions in the release me-
dium (pH, temperature, ionic strength, presence of surfactants) have 
profound effects on the nature of specific interactions, via the change of 
the conformation, protonation state, surface charge density (estimated 
by the zeta-potential) of the drug molecule and the aerogel backbone 
[69]. 
Strong interaction between the drug and the aerogel results in 
establishment of dynamic adsorption-desorption equilibrium between 
free and bound drug molecules. The rate of drug release is governed by 
the kinetic characteristics (lability) of the interfacial equilibrium, and 
the retained amount of drug is determined by the thermodynamic sta-
bility of the bound state. Drug adsorption is not favored on hydrophilic 
aerogels in aqueous media due to the facile hydration of the backbone, 
thus only a small portion of the drug is retained by the carrier matrix in 
equilibrium in most cases [75]. Ensuring sink conditions also effectively 
shifts the interfacial equilibrium towards desorption of the drug. It is 
important to note that a high kinetic barrier can exist for drug detach-
ment, which can significantly decrease drug release rate. Desorption of 
H-bonded drug molecules is thermodynamically favored due to hydra-
tion of binding sites, but the process is nevertheless, slow. In such cases, 
desorption can become the rate controlling step in drug release [74]. It 
was shown in the case of polyurea crosslinked random porous dysprosia 
aerogels that two processes are operational in determining release rate 
of loaded active ingredients (paracetamol, indomethacin, and insulin). 
The first process is the diffusion of dissolved drug molecules out of the 
pores, and the second process is the desorption of the H-bonded mole-
cules. Drug molecules close to the surface of the particles escape rapidly 
by diffusion. However, drug molecules deep in the small pores in close 
interaction with the aerogel skeleton are bound by H-bonds. The release 
rate is limited by the slow breaking of the H-bonds, resulting in equi-
librium desorption. These effects are spectacularly reflected in the dual 
character of the cumulative release curves (Fig. 4) [76]. 
2.2.3. Mass transport processes 
As discussed above, aerogels can erode, swell and collapse in contact 
with water. Importantly, effective mass transport in a drug delivery 
device is governed by the structure of the wet device, which can be very 
different from that of the dry aerogel. As an approximate trend, those 
Fig. 3. Release of deposited (A) ketoprofen in HCl (pH 1), and (B) ibuprofen in phosphate buffer saline (PBS, pH 7.2) from silica-gelatin aerogels of varying gelatin 
content, as shown in the legend. Drug release is diffusion limited from aerogels of high gelatin content due to the swelling of the carrier matrix and the encapsulation 
of the drug. Low gelatin content aerogels do not swell, and drug release is significantly faster. Reprinted from Keri et al. [71] with permission from Elsevier. 
Fig. 4. Release of active ingredients from polyurea crosslinked random porous dysprosia aerogels. The dual character of the release curves reflects that a portion of 
the drug is retained in the carrier due to the formation of strong H-bonds with the aerogel skeleton. Reprinted with permission from Bang et al. [76]. Copyright 
(2014) American Chemical Society. 
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aerogels that extensively erode do not swell or collapse (e.g. silica, 
alumina, cross-linked biopolymers), and erosion is negligible in those 
aerogels that extensively swell or collapse in water (e.g. natural 
biopolymers). 
In case of such aerogels that preserve their open porous structure in 
water, the rate limiting step in release is either the diffusion of water into 
the aerogel to dissolve the drug, or the diffusion of dissolved drug out of 
the particles. The diffusion of water into the pores is hindered in hy-
drophobic aerogels. Thus, the hydration of the device and the dissolu-
tion of the drug often limit the rate of drug release from hydrophobized 
silica and biopolymer aerogels. Unfortunately, modeling studies rarely 
deal with the rate of hydration of (hydrophobic) aerogel particles with 
respect to drug release mechanisms. In case of hydrophilic aerogels, the 
hydration of the carrier device and the dissolution of the deposited 
(amorphous or nanocrystalline) drug is usually much faster than the 
diffusion of drug molecules in the pores towards the release medium. In 
these cases, the factors regulating drug diffusion pathways (e.g., pore 
size and geometry, bottlenecks, tortuosity, length of channels) regulate 
the release rate. Therefore, the well-established semi-realistic models of 
drug release (e.g. Higuchi, Peppas, Korsmeyer, Hopfenberg) can usually 
be applied to hydrophilic open porous aerogel particles. These models 
are based on the mechanism of Fickian diffusion and take into account 
the distribution of the drug in the device and the shape of the device. In 
extreme cases, when the erosion of the aerogel is very fast, the rate of 
drug release can be proportional to the increasing net surface of the 
carrier device. The derivation, the general use and the limitations of 
such models are discussed in length in several review and opinion papers 
[63,64,77]. The application of simple semi-realistic models to describe 
drug release from aerogels is demonstrated through selected examples in 
the next section. 
Biopolymer aerogels swell and collapse in water leading to the for-
mation of hydrogel-like particles. Most often, the hydration of the aer-
ogel and the dissolution of the drug are very fast. When the collapse of 
the pore structure is faster than the diffusion of dissolved drug, the drug 
molecules are entrapped in the hydrogel-like matrix. In these situations, 
drug release becomes diffusion limited and modeling is often successful 
based on the mechanism on Fickian diffusion. Cumulative drug release 
can usually be described in these systems with the corresponding semi- 
realistic models, such as the Korsmeyer-Peppas model [46]. 
Interestingly, the rate limiting process can change even within one 
family of aerogels by the variation of aerogel structure. Silica-gelatin 
hybrid aerogels of low gelatin content are eroding carrier devices, but 
the rate of drug release becomes diffusion limited with the increase of 
the gelatin content of the carrier because of more and more expressed 
swelling. The mechanism change is reflected in the change of the shape 
of the release curves, as seen in Fig. 3 [71]. 
2.2.4. Mathematical drug release models 
Simple semi-realistic models can be utilized to describe cumulative 
drug release from aerogel carriers only in the most fundamental cases, 
because drug deposition into the aerogels without specific interaction 
with the skeleton and in the crystalline state is quite unlikely (see 2.1 (b) 
above). However, in this particular situation and for aerogels where 
erosion, swelling or collapse are either negligible or very well-defined, 
the drug release rate can be quite easily predicted and modeled, as 
discussed in the previous section. In these fundamental cases, mass 
transport processes can be combined into a single kinetic term, which 
leads to the well-known simple mathematical formulations, e.g., Higu-
chi, Peppas, Korsmeyer, Hopfenberg, and first-order models [63,64,77]. 
A good example is drug release from bacterial cellulose aerogels [78] 
that was perfectly predicted by Fickian diffusion equations, assuming 
that (i) the diffusion length is half of the thickness of the gel, and that (ii) 
once a certain water content is reached in a region of the matrix, the 
diffusion of the drug molecule starts [79]. Bacterial cellulose pre-gels 
were loaded with dexpanthenol and L-ascorbic acid (vitamin C) by 
soaking into the respective drug ethanolic solutions and subsequently 
dried using scCO2 to obtain the aerogels with the drug precipitated in-
side [78]. Loading isotherms showed a linear dependence of the amount 
of drug deposited in the aerogel and the drug concentration in the 
soaking solution, which suggested the absence of specific drug-cellulose 
interactions. Release profiles were recorded in water. Differently to 
many other biopolymer aerogels, bacterial cellulose aerogels did not 
collapse when immersed in water, therefore maintained their open 
porous network, which facilitated the access of water to the full struc-
ture. Thus, the release could be explained in terms of diffusion of the 
dissolved drug molecules from the inner aerogel to the release medium 
and, indeed, the rate was shown to depend on the thickness of the aer-
ogel monolith (Fig. 5). 
The Korsmeyer model [79], which considers simultaneous water 
diffusion into an open-porous matrix and drug diffusion out of it, fitted 
quite well the release profiles. In the case of bacterial cellulose aerogels, 
since no changes in volume occur during the release, the contribution of 
swelling to the release pattern can be neglected [78]. Diffusion has also 
been shown to be the main mechanism of curcumin release from non- 
swellable aerogels made of a polyvinylidene fluoride- 
hexafluoropropylene (PVDF-HFP) copolymer, and the release rate was 
regulated via an increase in polymer concentration, which increased the 
tortuosity of the diffusional pathway [80]. Similarly, ibuprofen release 
from silk fibroin aerogels that did not swell or lose any weight in 
phosphate buffer saline (PBS) of pH 7.4 in the time frame of their 
capability to sustain drug release (6 h) was perfectly modeled by Fickian 
diffusion [81]. 
The procedure followed to load the drug into the aerogels has also 
been shown to impact not only the drug adsorption yield, but also the 
drug release pattern because it changes the interactions between the 
cargo and the matrix. In a comparative study carried out with silica and 
alginate aerogels, Clinacanthus nutans (C. nutans) plant extracts were 
loaded either by wet impregnation (extracts obtained using ethanol or 
ethanol/water mixture) or supercritical impregnation with the main 
extract component phytol [82]. Silica aerogels exhibited the highest 
loading after supercritical impregnation, while alginate aerogels showed 
remarkably better loading when impregnated with the extracts. Alginate 
aerogels had the highest loading amounts under all conditions, dis-
regarding their smaller surface area compared to silica aerogels (126 vs. 
881 m2/g), which again revealed that not only the physical properties 
but also the nature of the aerogels may determine the adsorption of the 
active substances [52]. Importantly, phytol release tests (PBS pH 6.8, 
37 ◦C) with scCO2-impregnated aerogels evidenced the irreversible 
binding of the active compound to the aerogel skeleton [82]. Alginate 
aerogels impregnated with ethanol extracts (loading of 18.5 wt%) 
showed sustained release profiles, while those impregnated with 
ethanol/water extracts (loading of 9.6 wt%) released the components 
much faster, although still with a controlled pattern (Fig. 6). The effi-
cient loading of phenols and flavonoids from the extract suggested that 
the interactions between alginate and the hydrophobic compounds of 
the extract are quite strong. These interactions together with the low 
solubility in water of the components extracted in ethanol explain the 
slower release recorded for the alginate aerogels impregnated with the 
ethanol (100%) extract. Release patterns of both formulations fitted 
quite well to the Higuchi model (diffusion-controlled release) but, since 
swelling and erosion of aerogels were observed, the profiles were also 
fitted to the power-law model [83] (Eq. (1)), 
Mt
M∞
= ktn (1) 
In this equation, Mt represents the amount released at time t with 
respect to the total amount loaded (M∞), k is the release rate coefficient 
and n is an index of the release mechanism. The fitting revealed values of 
n of 0.61 for the formulation impregnated with the ethanol (100%) 
extract, indicative of anomalous (non-Fickian) diffusion. 
Very fast drug release takes place when there is practically no spe-
cific interaction between the drug and the aerogel, and the aerogel does 
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not swell or collapse, but rapidly erodes due to hydration. These con-
ditions are realized when hydrophobic drugs are deposited into hydro-
philic inorganic (e.g. silica) aerogels. The hydration and the consequent 
erosion of the aerogel are very fast and lead to the formation of open 
porous microparticles. Consequently, drug dissolution and diffusion out 
of the small particles are fast due to the large specific interface with the 
release medium. In such extreme cases, drug release rate is proportional 
to the time-dependent net surface area of the eroding device. Cumula-
tive release can be modeled by a semi-empirical equation proposed by 










In this equation, c0 is the initial loading of the drug dispersed uni-
formly in the device, r is the characteristic dimension of the device (e.g., 
the radius of spherical particles), n is a shape factor representing 
spherical (n = 3), cylindrical (n = 2) or slab geometry (n = 1), and k0 is a 
zero-order rate constant. The Hopfenberg model was originally derived 
for surface eroding carriers, where all mass transport leading to drug 
release add up to a zero-order process focused on the surface of the 
device. This model successfully describes the rapid release of ibuprofen 
and ketoprofen form quasi-spherical silica based aerogel particles, 
where facile hydration drives the detachment of the drug and the 
erosion of the device [71] (Fig. 7). 
In a case study, a series of mesoporous silica aerogels with varying 
density were synthesized and loaded with ketoprofen in scCO2 [85]. The 
mean pore size showed an inverse correlation with aerogel density, but 
loading was approximately the same for all aerogels (between 16 and 23 
wt%). Drug release in 0.1 M HCl medium was approximately five times 
faster than the dissolution of the pure drug, and it was the fastest from 
silica aerogel of the lowest density (0.033 g cm− 3) and largest mean pore 
size (24 nm). Cumulative release was successfully modeled by the first- 
order equation (Eq. (3)), 
Mt
M∞
= 1 − exp( − k1t) (3) 
In this equation k1 is the first-order rate coefficient describing the 
combined effect of mass transport processes controlling release rate. 
Fig. 5. Release profiles in water of dexpanthenol (left) and L-ascorbic acid (right) from bacterial cellulose aerogels of different thickness that had been loaded with 
the drug by immersion of the alcogels in a drug solution and then underwent scCO2 drying. Reprinted from Haimer et al. [78] with permission from John Wiley 
and Sons. 
Fig. 6. Release pattern of Clinacanthus nutans (C. nutans) plant extract from alginate aerogels loaded by wet impregnation with extracts in 100% ethanol (CN100) or 
50% ethanol (CN50). Reprinted from Mustapa et al. [82] with permission from Elsevier. 
C.A. García-González et al.                                                                                                                                                                                                                   
Journal of Controlled Release 332 (2021) 40–63
48
As discussed in Section 2.2.2, random porous and hierarchically 
porous polyurea crosslinked silica aerogels and dysprosia aerogels were 
loaded with paracetamol, indomethacin or insulin. The release of these 
active ingredients was investigated in 0.1 M HCl and in PBS media, 
yielding complicated multi-step release curves (Fig. 4). Nevertheless, 
release curves were successfully fitted with the first-order model com-
plemented by two additional sigmoidal components as additive terms. 
The mechanistic explanation is that the release of drug molecules closer 
to the surface is governed by diffusion (first-order term), but drug 
molecules deep in small pores are in adsorption-desorption equilibrium 
(sigmoidal terms) due to strong H-bonding with the aerogel skeleton 
[76]. 
As a final point, it has to be mentioned here that the effects of hy-
dration, specific interactions and mass transport have already been 
combined successfully into single comprehensive realistic models that 
give unprecedentedly deep mechanistic insights into drug release from 
porous silica carriers [86,87]. However, the application of these models 
is limited to very specific systems, and has to be re-evaluated for each 
carrier and drug combination in order to gain the desired mechanistic 
insights. 
3. Aerogels for oral administration 
Oral drug bioavailability depends on a very delicate balance among 
dose, solubility, permeability and pre-systemic metabolism [55,88]. 
Therapeutic outcomes may be notably enhanced when the drug is tar-
geted to or released in a specific region of the gastrointestinal tract that 
is more favorable in terms of drug physicochemical stability and/or 
permeability [89]. Additionally, the maintenance of drug levels for a 
prolonged time is required for drugs with narrow therapeutic index and 
for chronic treatments, which demands the development of oral for-
mulations able to precisely regulate the release rate [90]. In addition, 
reducing the administration frequency could be achieved by prolonging 
the residence time of the delivery system in the gastrointestinal tract by 
means of mucoadhesion, for which mucoadhesive polymers and par-
ticulate formulations could be used [91]. Examples of aerogels that can 
successfully contribute to the achievement of the above reported desired 
performances are analyzed in the next subsections. 
3.1. Aerogels as drug solubilizing aids 
Drugs that exhibit solubility values that prevent complete dissolution 
of the required dose in a reasonable time frame for oral absorption are 
classified as Class II or Class IV in the Biopharmaceutics Classification 
System (BCS) depending on whether the membrane permeability is high 
or low, respectively [88]. More than 40% of current drugs on the market 
are poorly-water soluble, which limits the amount that can be orally 
absorbed and, in turn, the bioavailability and the therapeutic efficacy. 
Low aqueous solubility also challenges the formulation and preclinical 
and clinical evaluation of most of the new chemical entities [92]. 
Among the wide variety of drug solubilization strategies, preparation 
of solid dispersions or complexes (e.g., cyclodextrins, polyelectrolytes) 
in which the drug molecules remain individualized or as amorphous 
small particles has largely been proved successful to enhance drug 
dissolution rate and apparent solubility in the gastrointestinal fluids 
after oral administration [93]. Similarly, drug loading into aerogels 
using supercritical fluids commonly leads to aerogels impregnated with 
amorphous drug particles. Drug formulation in silica or hydrophilic 
biopolymer-based aerogels has also been shown to increase dissolution 
rate mainly due to drug amorphization and a sharp increase of the 
surface area. However, in the case of aerogels, the term solid dispersion 
is not accurate since drug molecules or particles remain adsorbed onto 
the pore walls. They are not integrated into the aerogel skeleton itself 
but dispersed onto its surface [53]. 
Differently to the drug recrystallization commonly observed when 
the aerogels are processed by freeze-drying [40], the interactions of the 
drug molecules with the aerogel skeleton and the confinement of solid 
drug particles (either as amorphous or as nanocrystalline metastable 
polymorphs) notably prevent crystal growth and recrystallization into 
stable polymorphs [94]. Table 1 summarizes relevant examples of the 
interest of aerogels as fast or immediate release oral dosage form. 
Early reports on scCO2 impregnation of hydrophilic silica aerogels 
with drugs evidenced the capability of the mesopores to host a variety of 
molecules of different polarity: ketoprofen, miconazole, terfenadine, 
dithranol, niclosamide, griseofulvin, and nimesulide, among others 
[54,72]. After impregnation, the drugs remained in amorphous state, 
which notably enhanced the dissolution rate (4-5-fold) either in 0.1 N 
HCl or PBS pH 7.4, compared to the unprocessed crystalline drug par-
ticles. Hollow silica aerogel microspheres prepared from rice husk ash 
(338.9 m2/g surface area and 1.7 cm3/g pore volume) and impregnated 
with ibuprofen (0.47 g/g) using scCO2 released 80% of the drug payload 
within the first 15 min after immersion in 0.1 N HCl solution doped with 
1% sodium dodecyl sulfate (Table 1, entry 1). The unprocessed crys-
talline drug dissolved only 11% in the same time interval [95]. Subse-
quent improvements in the structure of the microspheres allowed for 
100% ibuprofen release in 15 min [96]. Hydrophilic aerogel micro-
spheres from rice husk ash generated with optimized composition and 
sol-gel emulsion conditions showed improved capability to adsorb 
ibuprofen (up to 0.87 g/g) both as amorphously dispersed and as 
nanocrystals [57]. The aerogels had a burst release of ~80% of the 
loaded drug in the first 30 min followed by a sustained release. The 
coexistence of fast dissolving amorphous drug and small crystals with 
high surface contact area with the release medium together with a fast 
disintegration of the microspheres explain the fast release. 
Since silica aerogels are biocompatible but the biodegradability and 
fate in human body are highly variable [97], hybrid systems with bio-
polymers and biopolymer-solely aerogels are gaining increasing atten-
tion for drug formulation. In a comprehensive research, fourteen hybrid 
aerogels prepared with different silica/gelatin ratios were investigated 
as drug solubility enhancers [74]. The aerogels were prepared by 
combining silica and gelatin and, then, hydrophobic moieties were 
introduced to tune the stability in contact with aqueous medium and 
also the strength of the interactions with three low solubility, weakly 
acidic drugs chosen for the study: the nonsteroidal anti-inflammatory 
(NSAID) drugs ibuprofen (pKa = 4.40) and ketoprofen (pKa = 4.76), 
and the antiplatelet agent triflusal (pKa = 4.15) (Table 1, entry 2). An 
increase in the gelatin content from 3% to 24% caused a decrease in 
surface area from 700 to 300 m2/g and in pore volume from 2.1 to 1.2 
cm3/g. Triflusal, the drug showing the highest solubility in scCO2, was 
adsorbed to a larger extent (0.25–0.29 g/g) compared to ibuprofen 
(0.19–0.24 g/g) and ketoprofen (0.11–0.15 g/g). The increase in hy-
drophobic groups did not enhance drug loading but caused a slight 
decrease. XRD and differential scanning calorimetry (DSC) analysis 
suggested that the drugs were molecularly dispersed on the inner surface 
of the aerogel. Drug solubility tests were carried out in media of pH 2.0 
Fig. 7. Rapid release of deposited ketoprofen (KET) in HCl pH 1.0 (A) and 
ibuprofen (IBU) in PBS pH 7.2 (B) from silica-gelatin aerogels of low gelatin 
content (given in the legend). Drug release rate was proportional to matrix 
erosion rate, and cumulative drug release was successfully simulated using the 
Hopfenberg model (Eq. (2)). Continuous lines show the best fits. Reprinted from 
Keri et al. [71] with permission from Elsevier. 
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(10 mM HCl) and pH 6.7 (PBS). As expected, unprocessed crystalline 
ibuprofen, ketoprofen and triflusal particles exhibited a remarkable pH- 
dependent solubility; the solubility at pH 2 being 0.06, 0.26 and 0.69 
mg/mL, respectively. At pH 6.7, the particles readily dissolved, and the 
solubility was above 0.70 mg/mL. Triflusal is highly unstable in neutral- 
alkaline aqueous medium, but encapsulation within silica aerogels was 
previously demonstrated to enhance drug stability during storage for 6 
months at 21 ◦C and 60–65% relative humidity (RH) due to the acidic 
environment provided by the SiO2 matrix [98]. Encapsulation within 
hybrid silica/gelatin aerogels without hydrophobic moieties led to a 
burst of more than 50% released at pH 2 in the first hour, and to a nearly 
complete release at pH 6.7 in the same time frame. Hydrophobically 
modified (silylated) aerogels showed more sustained release, particu-
larly at pH 2 (Fig. 8), due to a strengthening of the drug-matrix in-
teractions through hydrogen bonds. 
Improvements in ibuprofen release rate have also been observed 
after scCO2-impregnation of alginate aerogels (Table 1, entry 3) [35] 
and carrageenan aerogel microparticles (65–154 μm) obtained via the 
emulsion-gelation technique (Table 1, entry 4) [99]. Carrageenan aer-
ogel microparticles contained the drug in amorphous state and provided 
Table 1 
Examples of aerogels suitable for fast or immediate oral release reported in the last decade.  
Entry Aerogel composition Drug Loading method Release conditions and outcomes Reference 
1 Hollow rice husk ash silica 
aerogel microspheres 
Ibuprofen scCO2 impregnation of 
preformed aerogel 
0.1 N HCl with 1% sodium dodecyl sulfate. Faster drug 
release than crystalline drug (80% vs. 11% in 15 min) 
[95] 
2 Silica and gelatin hybrid aerogels 
with various functionalities 
Ibuprofen, ketoprofen 
and triflusal 
scCO2 impregnation of 
preformed aerogel 
pH 2 and 6.7 medium. Aerogels showed burst followed by 
sustained release at acid pH and rapid release at pH 6.7 
[74] 
3 Alginate Ibuprofen scCO2 impregnation of 
preformed aerogel 
Buffer pH 7.2. Compared to crystalline ibuprofen, alginate 
aerogels showed faster release rate (<90% in 2 h) 
[35] 
4 Carrageenan cross-linked with 
KCl 
Ibuprofen scCO2 impregnation of 
preformed aerogel 
Buffer pH 7.2. Compared to crystalline ibuprofen, the 
aerogels showed immediate release 
[99] 
5 Alginate Ketoprofen Dug added to alginate 
dispersion before cross- 
linking 
0.1 M HCl for 2 h, then phosphate buffer pH 6.8. Burst at 
acid pH and complete release in few minutes at pH 6.8 
[100] 
6 Alginate Ketoprofen, 
nimesulide, and 
loratadine 
scCO2 impregnation of 
preformed aerogel 
Release tests in pH 6.8. Ketoprofen and nimesulide dissolved 
in less than 30 min at pH 6.8. Loratadine dissolved in 5 min 
at pH 1.2. 
[101] 
7 Maize starch Ketoprofen, 
nimesulide, and 
diclofenac 
scCO2 impregnation of 
preformed aerogel 
Phosphate buffer saline pH 7.4. Complete release in few 
hours. 
[102] 
8 Silica, starch, alginate Ibuprofen scCO2 impregnation of 
preformed aerogel 
Phosphate buffer pH 6.8. More than 90% released in 30 min. [103] 
9 Maize starch Vitamin E and vitamin 
K3 
scCO2 impregnation of 
preformed aerogel 
Phosphate buffer pH 7.4. The aerogels shortened to approx. 
1 h the dissolution time. 
[106]  
Fig. 8. Release profiles of ibuprofen (Ibu), ketoprofen (Ket) and triflusal (Trf) from hybrid silica/gelatin (3 wt%) aerogels without hydrophobic groups (H3) or with 
silylated groups (H3_sil) recorded at 37 ◦C and pH 2 or pH 6.7. Reprinter from Veres et al., [74] with permission from Elsevier. 
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>90% release in less than 10 min (PBS pH 7.2). Interestingly, the au-
thors carried out physical and chemical stability studies by placing the 
ibuprofen-loaded aerogels in amber glass bottles in chambers at 30 and 
40 ◦C and 75% RH for 3 months. The aerogels remained chemically 
stable but, depending on the carrageenan type and the relative amount 
of drug loaded, crystallization of ibuprofen was observed at 40 ◦C. It was 
suggested that aerogels prepared with kappa-carrageenan and low drug 
contents had adequate physical stability and prevented better drug 
crystallization than the other counterparts [99]. Nevertheless, drug 
release profiles after storage were not re-evaluated. 
As an alternative to emulsion preparation, spherical aerogel particles 
can be generated by prilling, i.e. using a vibrating nozzle device that 
produces fine droplets, which avoids oil phase removal and could be 
more easily scaled-up. Precisely sized drops of alginate solution con-
taining ketoprofen were collected in a bath containing the cross-linker in 
an aqueous medium or in ethanol, and dried using scCO2 after solvent 
exchange. The obtained aerogels (2.5–3.1 mm) showed excellent sphe-
ricity [100]. Aerogels cross-linked in the aqueous medium contained 
ketoprofen in amorphous state and showed fast release (75% dose in 30 
min) when immersed in simulated gastric fluid (Table 1, entry 5). 
Xerogels of similar composition but dried in a conventional oven 
(shrunk structure) only released 20% of the cargo after 120 min. Aero-
gels cross-linked in ethanol had ketoprofen in crystalline state and the 
release pattern was intermediate to the other formulations, with 40% 
dose released in 30 min. Using a similar approach, dripping of alginate 
solution into the crosslinking bath and subsequent scCO2 drying and 
drug impregnation has been proved useful to produce aerogels particles 
(2.7 mm; 512 m2/g) loaded with ketoprofen (18–28 wt%), nimesulide 
(5–14 wt%) or loratadine (24–30%) [101]. The drugs remained in 
amorphous state for six months of storage. Release tests in pH 6.8 me-
dium evidenced that ketoprofen and nimesulide can be fully dissolved in 
less than 30 min. Loratadine release in pH 1.2 medium was completed in 
less than 5 min (Table 1, entry 6). These fast release profiles were in 
good agreement with those reported for nimesulide, ketoprofen and 
diclofenac sodium when scCO2 impregnated into monoliths of maize 
starch aerogel [102] (Table 1, entry 7). 
The impact of the role of the aerogels as drug solubilizing aids was 
evidenced for ibuprofen as a remarkable increase in oral bioavailability. 
Compared to an oral suspension of the unprocessed free drug, the 
formulation of ibuprofen in silica, starch or alginate aerogels accelerated 
drug release rate (Table 1, entry 7) and increased more than 2-fold the 
relative bioavailability [103] (Fig. 9). Similarly, encapsulation of the 
antifungal itraconazole in starch aerogels provided a 3-fold increase in 
relative bioavailability compared to marketed products [104]. Oral 
bioavailability of phytosterol has been also shown to increase from 3% 
when the crude crystalline compound was directly administered, to 35% 
when supercritically impregnated into starch aerogels [105]. 
A maize starch-based aerogel has been shown suitable for loading 
high amounts of lipophilic vitamin E (α-tocopherol) and vitamin K3 
(menadione) using scCO2 adsorption [106]. Solubilities of vitamin E and 
vitamin K3 in scCO2 at 15 MPa in the 40 to 60 ◦C interval were in the 3–8 
and 1.5–2 mg/g range, respectively. The adsorption isotherms revealed 
the remarkable effect of temperature (40 ◦C/15 MPa or 60 ◦C/15 MPa) 
on the adsorption isotherms (Fig. 10). The aerogels showed a highly 
efficient loading (145 mg vitamin E/g and 100 mg vitamin K3/g), and 
the release tests carried out in PBS pH 7.4 revealed noticeably fast 
release (Table 1, entry 9). Compared to unprocessed vitamin E and 
vitamin E/aerogel physical mixtures that required 20 h in achieving 
100% dissolution, vitamin E formulated in aerogels completed the 
dissolution in 75 min. In parallel, unprocessed vitamin K3 and its 
mixture with aerogels required 5 h to complete the dissolution, while 
vitamin K3-loaded aerogels provided completed dissolution in 80 min 
[106]. Taking into account the recommended dietary allowance (RDA) 
of vitamin E (15 mg) and vitamin K3 (0.1 mg), tablets containing 100 mg 
vitamin E-loaded aerogels and 1 mg vitamin K3-loaded aerogels could 
fulfil the daily needs of both vitamins. 
Formulation of hydrophobic drugs into hydrophilic aerogels while 
still preserving the crystalline structure of the drug may be also feasible. 
Compared to amorphization reported above, formulation of crystalline 
forms has the advantage of improved stability [107]. Carbon aerogels 
have been designed to promote the π-π interactions with lipophilic drugs 
such as coenzyme Q10. Functionalization of the carbon aerogels with 
graphene oxide has been shown to enhance the rate and the amount of 
drug loaded (up to 0.05 mg/mg) when soaked in a drug solution in 
acetonitrile. The aerogels were air-dried at room temperature. Coen-
zyme Q10 was shown to be crystalline but the XRD pattern was different 
from that of the bulk drug, which has been explained by the confining 
effect that the aerogel pores may have on the crystal growth [108]. The 
effects on drug release are still to be elucidated. 
Fig. 9. Blood levels of ibuprofen after oral administration to Wistar rats of the same drug dose as oral dispersions of drug-loaded aerogels or unprocessed free drug. 
Reprinted from Lovskaya et al. [103] with permission from Elsevier. 
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3.2. Aerogels for sustained and stimuli-responsive release 
Polymer-based aerogels are gaining increasing interest when 
searching for sustained oral release. The work in the field is still incip-
ient and many unanswered questions remain. For example, most reports 
on aerogels for sustained release did not consider the stability of the 
aerogels in the presence of natural surfactants and human and bacteria 
enzymes typical of the small and large intestine. The manufacture of 
aerogel-based dosage forms (e.g., suspension, capsule, and tablet) while 
keeping aerogels integrity is another issue to be investigated. Never-
theless, the already available information points out some interesting 
performances of the aerogels as evidenced in the next lines below. 
Table 2 summarizes relevant examples of the interest of polymeric 
aerogels as components of sustained and stimuli-responsive release oral 
dosage form. 
Starch and alginate aerogels either as monoliths or microspheres 
were one of the first investigated polysaccharide-based aerogels for drug 
delivery [35]. Starch aerogels from potato and Eurylon7 amylomaize 
were evaluated for the encapsulation of ibuprofen and paracetamol. 
Different loading protocols were followed considering the solubility of 
each drug: ibuprofen was loaded by scCO2 impregnation of the pre-
formed aerogel (Table 2, entry 1), while paracetamol was loaded 
through solvent exchange in drug-saturated ethanol before scCO2 drying 
[109] (Table 2, entry 2). Eurylon7 starch aerogel loaded higher amounts 
of ibuprofen (22 vs. 10 wt%) and paracetamol (25 vs. 10 wt%) than 
potato starch aerogel, which may be related to the higher surface area of 
the former (90.3 vs. 72.5 m2/g). Paracetamol was partially crystalline 
and its release in PBS pH 7.2 was completed in 2 h, which was slightly 
slower than unprocessed crystalline paracetamol. Differently, the 
ibuprofen release was sustained for more than 10 h despite being 
adsorbed as amorphous solid. Eurylon7 starch aerogel collapsed and 
disintegrated in contact with the release medium and released >60% in 
4 h. Potato starch aerogel released less than 40% in the same time frame 
because of the higher stability of this aerogel in water [109]. Corn and 
pea starch aerogel microspheres obtained through the combination of 
emulsion-gelation and supercritical drying were investigated as keto-
profen carriers loaded by supercritical impregnation [110]. As in the 
case of silica aerogels, the loaded drug (11.5 wt%) did not display 
crystalline peaks, but the loading was one-order of magnitude larger and 
the release was more sustained from the starch aerogels. Ketoprofen 
release rate was slower than the dissolution rate of the crystalline drug 
in PBS pH 6.8, although the release was completed within 2 h (Table 2, 
entry 3). 
Improved control of drug release was recorded for hybrid aerogels of 
multiwalled carbon nanotubes (CNTs) and konjac glucomannan and 
processed using freeze-drying. The aerogels were soaked in a 5-fluoro-
uracil aqueous solution [111] (Table 2, entry 4). Konjac glucomannan 
aerogels without CNTs showed burst release, with most drug released in 
less than 2 h, regardless of the pH of the medium. An increase in the CNT 
content attenuated the burst effect and prolonged the release for more 
than 11 h due to strong drug-CNT hydrogen bonding [111]. Porosity and 
pore features of the aerogels were only qualitatively described, which 
makes comparisons with other aerogels difficult. Mesoporous carbon 
aerogels have shown remarkable capability to load drugs by soaking in 
drug solutions prepared in ethanol, as also demonstrated for ibuprofen 
[112]. Carbon aerogel monoliths of mean pore size 10 nm and 20 nm 
loaded 18.2 and 22.9 wt% ibuprofen, respectively, showed excellent 
compatibility with intestinal cells in vitro, and sustained drug release in 
both fasted and fed intestinal simulated fluids for several hours (Table 2, 
entry 5). 
Barley and yeast β-glucan aerogels have been shown suitable to host 
relatively high amounts of the NSAID acetylsalicylic acid and to sustain 
its release. These two types of β-glucan significantly differ in chain 
structure and gelling capability. Barley glucan, a (1–3, 1–4)-β-glucan, is 
water soluble and requires a minimum concentration of 4 wt% to form 
gels upon cooling. Conversely, yeast glucan, a (1–3, 1–6)-β-glucan, is not 
soluble in water and requires only 2.5 wt% to form heat-induced gels. 
The respective alcogels were processed with scCO2 in the presence of 
acetylsalicylic acid for drug adsorption and drying in one step [43]. 
Barley glucan aerogels had larger surface area (189 vs. 173 m2/g), pore 
volume (0.713 vs. 0.563 cm3/g), mean pore size (15.8 vs. 13.7 nm), and 
bulk density (69 vs. 35 Kg/m3), but lower capability to uptake water 
(800 vs. 1400 wt%). The amount of acetylsalicylic acid notably depen-
ded on the conditions of supercritical processing but ranged between 8 
and 15 wt% for all aerogels. No data about crystallinity was reported. 
Drug release tests carried out in PBS pH 7.4 at 37 ◦C evidenced 
remarkable differences between both glucan aerogels (Table 2, entry 6). 
Barley glucan aerogel showed 3 h lag time followed by an exponential 
increase in the release rate in the next 3 h and then, the release rate 
slowed down. Yeast glucan aerogel released 20% of the loaded drug in 
the first 2 h, followed by sustained release along 24 h. The higher 
capability of yeast glucan aerogels to swell in the aqueous medium 
without dissolution has been pointed out as the reason of the differences 
in drug release rate [43]. The delayed release observed for barley glucan 
aerogel proves that the drug was efficiently adsorbed inside the aerogel 
and not deposited on the surface, and that the release requires the 
previous swelling of the skeleton (wetting and relaxation of the chains). 
Thus, a combined contribution of matrix swelling and drug diffusion 
Fig. 10. Adsorption isotherms of vitamin E (α-tocopherol, TOC) and vitamin K3 (menadione, MEN) into maize starch aerogels (MSA) at 15 MPa and 40 or 60 ◦C after 
48 h exposition. Reprinted from De Marco et al. [106] with permission from Elsevier. 
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governed the release kinetics. 
Cellulose nanofiber aerogels processed applying freeze-drying have 
been investigated as gastro-retentive formulations due to their float-
ability and mucoadhesive performances [113]. The nanofibers were 
loaded with the anti-cancer agent bendamustine hydrochloride (~19 wt 
%) by soaking in a drug solution and then freeze-dried using mannitol as 
cryoprotectant. Total floating time in HCl buffer pH 1.2 and PBS pH 7.4 
was similar and close to 450 min. The nanofiber aerogels showed pref-
erential swelling in PBS pH 7.4 (225%) than in buffer pH 1.2 (189%). 
Bendamustine release was sustained in both pH 1.2 (69% released in 24 
h) and pH 7.4 (78% released in 24 h) (Table 2, entry 7). The release 
profiles fitted to the Korsmeyer-Peppas model with n values of 0.613, 
suggesting once again the combined contribution of drug diffusion and 
matrix swelling. Drug pharmacokinetics was evaluated in a Wistar rat 
model for pure drug solution and the drug-loaded aerogels after oral 
administration and compared to intravenous administration of the drug 
solution. Relevantly, the nanofiber aerogels provided 5.66-fold and 
3.25-fold higher area-under-the-curve (AUC) than the intravenous in-
jection and the oral solution, respectively (Fig. 11). 
In a comparative study, cellulose nanofiber aerogels of different 
sources were evaluated regarding their capability to sustain the release 
of the steroid beclomethasone dipropionate [20] (Table 2, entry 8). 
Nanoparticles of this drug were coated with amphiphilic hydrophobin 
proteins and dispersed in the cellulose nanofibers before freeze-drying. 
Aerogels made from red pepper cellulose or microcrystalline cellulose 
released the drug very rapidly (60% in 5 min), while those prepared with 
bacterial cellulose, quince seed and oxidized birch cellulose provided 
sustained drug release (10% released in 10 min; prolonged release for 
700 min) [20]. The differences in capability to regulate drug release 
clearly correlated with the strength of the interactions of the drug 
nanoparticles with the cellulose skeleton. 
Alginate aerogels have shown by themselves certain pH- 
Table 2 
Examples of aerogels suitable for oral sustained release or stimuli-responsive release reported in the last decade.  
Entry Aerogel composition Drug Loading method Release medium and outcomes Reference 
1 Potato starch and Eurylon 7 
starch 
Ibuprofen scCO2 impregnation of preformed 
aerogel 
Buffer pH 7.2. Compared to crystalline ibuprofen, potato 
starch aerogels showed slower release rate (<50% in 6 h) 
[109] 
2 Potato starch and Eurylon 7 
starch 
Paracetamol Solvent exchange in drug-saturated 
ethanol before scCO2 drying 
Buffer pH 7.2. 100% released in 2 h [109] 
3 Corn and pea starch Ketoprofen scCO2 impregnation of preformed 
aerogel microspheres 
Buffer pH 6.8; ~50% released in the first 1 h followed by 24 h 
sustained release 
[110] 
4 Multiwalled carbon 
nanotubes (CNTs) and 
konjac glucomann 
5-fluorouracil Soaking in a drug solution Buffers pH 1.2 and 6.8. Sustained release for more than 11 h. [111] 
5 Carbon Ibuprofen Soaking in a drug solution Fasted and fed intestinal simulated fluids. Less than 50% 
released after 2 h. 
[112] 
6 Barley glucan and yeast 
glucan 
Acetylsalicylic acid Simultaneous drug impregnation 
and supercritical drying. 
Buffer pH 7.4. Barley glucan aerogel showed 3 h lag time 
followed by an exponential increase in release rate. Yeast 
glucan aerogel released 20% drug in the first 2 h followed by 
sustained release along 24 h 
[43] 
7 Cellulose nanofiber Bendamustine 
hydrochloride 
Soaking in a drug solution, and 
freeze-drying 
Buffers pH 1.2 and 7.4. Sustained release for 24 h. [113] 
8 Cellulose nanofiber Beclomethasone 
dipropionate 
Drug nanoparticles dispersed with 
the nanofibers and freeze-dried 
The aerogels were conditioned in gelatin capsules (size 0) and 
placed in 40 mL of 0.3% SDS. Aerogels made from bacterial 
cellulose, quince seed and oxidized birch cellulose sustained 
drug release for more than 10 h. 
[20] 
9 Alginate cross-linked with 
Ca2+
Ketoprofen scCO2 impregnation Buffers pH 1.2 and 6.8. Sustained release for more than 6 h. [52] 
10 Alginate, pectin and pectin- 
alginate cross-linked with 
Zn2+
Diclofenac Drug added to the polysaccharide 
dispersion 
Buffers pH 1.2 and 6.8. Sustained release for more than 6 h. [114] 
11 Alginate cross-liked with 
Fe3+
Ibuprofen scCO2 impregnation of the aerogels 
with ibuprofen w/o ascorbic acid 
Buffers pH 2.2 and 7.4. Release faster in pH 7.4 due to erosion 
of aerogels. The release can be accelerated incorporating 
ascorbic acid into aerogels, which reduces Fe3+ to Fe2+upon 
hydration. 
[115] 
12 High-methoxyl pectin Nifedipine Soaking in ethanol phase or scCO2 
impregnation 
Buffers pH 1.2 and 6.8. Minor release at gastric pH, prolonged 
release at pH 6.8 for more than 6 h. 
[116] 
13 Guar and xantham gum Nifedipine Soaking in ethanol phase Buffers pH 1.2 and 6.8. Minor release at gastric pH, prolonged 
release at pH 6.8 for more than 12 days. 
[117] 




Drug added to pectin dispersion 
before Ca2+ cross-linking 
Buffer pH 6.5. Citrus pectin aerogels prolonged drug release 
for 6 h, compared to less than 1 h from apple pectin aerogels. 
[118] 
15 Chitosan, carboxymethyl 
cellulose and graphene 
oxide 
5-fluorouracil Soaking in a drug solution in water 
followed by freeze-drying 
Buffers pH 1.2, 5.5 and 7.4. Minor release at pH 1.2; faster 
release at pH ≥ 5.5. 
[119] 
16 Graphene oxide and vitamin 
C 
Doxorubicin Drug added during nanoparticles 
preparation 
Buffers pH 5.4 and 7.4. Sustained but faster release at pH 5.4 
than 7.4. 
[120] 
17 Silica Paclitaxel Soaking in drug solution and freeze- 
drying 
Simulated gastric (pH 1.5) and intestinal (pH 6.5) fluids. After 
15 days, aerogels released less than 10% at pH 1.5 and about 
50% at pH 6.5. 
[121] 
18 Halloysite nanoclay Ibuprofen and 
dexamethasone 
Dual loading. Ibuprofen added 
before cross-linking; 
dexamethasone loaded by soaking 
Buffers pH 1.2 and 7.4. Sustained release for 2 days. Minor 
effect of pH. 
[122] 
19 Alginate grafted NIPA; and 
NHMAM 
Indomethacine Drug added before freeze-drying Buffers pH 2.1 and 7.4. Release rate sustained for several 
hours, but faster at pH 7.4 and 42 ◦C than at 25 ◦C. 
[123] 
20 Whey protein Ketoprofen scCO2 impregnation Buffers pH 1.2 and 6.8. Anomalous non-Fickian drug release, 
faster at pH 6.8 than at 1.2 
[125] 
21 Whey protein, egg white 
protein or sodium caseinate 
Fish oil scCO2 impregnation Saliva, gastric and intestinal mimicking media. Resistance 
against digestion and selective release in the intestine 
mimicking environment. 
[126]  
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responsiveness promoting the release of ketoprofen under acidic pH 
conditions despite that at such pH drug solubility is lower. Indeed, 
alginate aerogel microspheres prepared via emulsion-gelation (calcium 
crosslinking) and scCO2 drying (116 μm; 524 m2/g) and supercritically 
impregnated with ketoprofen (11.8 wt%) led to release profiles that 
fitted quite well to Korsmeyer-Peppas model (Table 2, entry 9). The 
exponent n was close to 0.4 at both pH values 1.2 and 6.8, but the release 
rate coefficient was higher at acidic pH (16.7 vs. 12.8 min-n) [52]. This 
finding can be attributed to a weakening of the aerogels structure in HCl 
medium as the protons compete with the ionic crosslinking. Interest-
ingly, the divalent counterion used to crosslink alginate seems to play a 
relevant role in the feasibility of obtaining sustained release formula-
tions. Compared to the commonly used calcium ions, aerogels made of 
alginate, pectin and pectin-alginate crosslinked with zinc ions showed 
more prolonged release of diclofenac (Fig. 12) [114]. Differently to 
calcium crosslinked aerogels, those crosslinked with zinc loaded more 
drug, did not erode in simulated gastric fluid, and swelled more (58% vs. 
34%) in PBS pH 6.8. Strontium cross-linked aerogels showed interme-
diate performance. At a similar concentration, zinc provided denser 
skeletons probably because these ions can interact with more binding 
sites in the alginate and pectin chains. Zinc-crosslinked pectin aerogels 
did not release diclofenac when immersed in simulated gastric fluid for 
1 h and sustainedly released 80% of the cargo for 6 h when transferred to 
PBS pH 6.8, performing as an enteric formulation [114] (Table 2, entry 
10). In another study, release profiles from alginate aerogels crosslinked 
with Fe(III) (~400 m2/g) and impregnated with ibuprofen (35–40 wt%) 
were tuned by the addition of ascorbic acid (3.4–4.3 wt%) during scCO2 
impregnation (Table 2, entry 11). The aerogels showed an increase in 
release rate at pH 7.4 compared to pH 2.0, but the release rate was 
accelerated for aerogels containing ascorbic acid due to the capability of 
this reducing agent to transform Fe(III) into Fe(II), which weakens the 
crosslinking [115]. 
Pectin aerogels have also been tested for sustained but complete 
release of nifedipine, a BCS-Class II drug, after oral administration. 
High-methoxyl pectin aerogels (386 m2/g surface area) were obtained 
by gelling of aqueous pectin dispersions (tablet-like shape) which were 
placed into contact with ethanol and then underwent scCO2 drying. 
Nifedipine was loaded either during solvent exchange (in ethanol) or 
through supercritical adsorption. The loading was higher in the first 
option (22 vs. 13 wt%) but in both cases the drug remained amorphous 
[116]. Minor release was recorded after 2 h in gastric fluid due to small 
matrix swelling, but the release rate notably accelerated when the aer-
ogels were transferred to a buffer medium of pH 6.8 (Table 2, entry 12) 
due to swelling and erosion of the aerogels. Supercritically loaded 
nifedipine was released in 6 h, while aerogels loaded by soaking in 
ethanol sustained the release for 10 h. Applying similar gelling and 
nifedipine loading in ethanol, low-methoxyl pectin, alginate, guar, and 
xanthan gum aerogels were generated [117]. All these aerogels exhibi-
ted pH-responsive erosion; they swelled in aqueous medium, but the 
swelling was faster, and the erosion was triggered when transferred from 
pH 1.2 to pH 6.8 medium. Nifedipine release from alginate and pectin 
aerogels was completed in 5 h at pH 6.8. Differently, nifedipine release 
from guar and xantham gums aerogels was prolonged for more than 12 
days (Table 2, entry 13) due to the high stability in physiologically 
fluids, which may be useful for drug delivery using other administration 
routes. Also, the pectin source determined the capability of the aerogels 
to regulate drug release. Apple pectin aerogels (Ca(II) crosslinked) 
released the entire theophylline and nicotinic acid cargos within less 
than 1 h, while citrus pectin aerogels (Ca(II) crosslinked) sustained the 
release of any of these drugs for 6 h in buffer pH 6.5 [118] (Table 2, 
entry 14). Both apple and citrus pectin are low-methoxyl pectins but the 
small differences in degree of esterification (DE) and degree of amida-
tion (DA) may interfere in the crosslinking process; citrus pectin with 
lower DE and higher DA was strongly and more uniformly crosslinked. 
Aerogels can also be endowed with pH-responsive release properties 
by incorporating polycationic chitosan and polyanionic carboxymethyl 
cellulose. These two polysaccharides were combined with graphene 
oxide, crosslinked with Ca(II) ions, and freeze-dried to produce hybrid 
aerogel microspheres [119]. The anticancer agent 5-fluorouracil was 
loaded by soaking the aerogel in a drug solution followed by freeze- 
drying (Table 2, entry 15). The amounts released after 10 h at pH 1.2, 
5.5 and 7.4 were 26, 51 and 68%, respectively, and the release kinetics 
could be described by Fickian diffusion [119]. Aiming to enhance the 
drug release under the acidic pH of solid tumors, graphene aerogel 
nanoparticles were prepared by reduction of graphene oxide sheets with 
vitamin C, sonication to break them into nanoparticles (180 nm), and 
loaded with doxorubicin [120]. In the first 24 h, the percentage of 
Fig. 11. Bendamustine blood levels after intravenous (iv) administration, oral 
administration of a drug solution and oral administration of drug-loaded cel-
lulose nanofibers aerogels to Wistar rats. Reprinted from Bhandari et al. [113] 
with permission from Dove Medical Press. 
Fig. 12. Diclofenac release profiles in PBS pH 6.8 from (A) pectin, (B) alginate and (C) alginate-pectin aerogels crosslinked with calcium (PC, AC and APC, 
respectively), strontium (PS, AS and APS, respectively), or zinc (PZ, AZ and APZ, respectively). Reprinted from Tkalec et al. [114] with permission from Elsevier. 
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released doxorubicin was 40% at pH 7.4 and 60% at pH 5.4, but in this 
case, the faster release at pH 5.4 may be due to enhanced solubility of 
the encapsulated drug (Table 2, entry 16). 
The benefits of aerogels as oral carriers of antitumor drugs that can 
attenuate the drawbacks of parenteral administration have been high-
lighted in a recent study. Silica aerogels were loaded with the poorly- 
water soluble anticancer agent paclitaxel by soaking them in a drug 
solution, freeze-drying and processing by spray-drying as spherical mi-
croparticles (2.56 μm) [121]. The aerogels remarkably increased the 
apparent drug (amorphous) solubility in water. In vitro release tests 
carried out in simulated gastric (pH 1.5) and intestinal (pH 6.5) fluids 
revealed that the drug can be selectively released in the intestine due to 
the pH-dependent release rate (Table 2, entry 17). In pH 6.5 medium, 
after a burst release of 20% in the first 24 h, the aerogels sustained the 
release for more than one month. Drug transport studies by using the 
Caco-2 cell monolayer model revealed that the aerogels increased drug 
permeability by 15- to 20-fold. The uptake of the paclitaxel-loaded silica 
aerogels into Caco-2 cells was increased 6- to 10-fold with respect to free 
drug. Enhanced uptake by tumor cells was also confirmed by using a 
breast cancer cell line (MCF7 cells). Moreover, the formulation into 
aerogels significantly decreased the viability of the tumor cells, showing 
lower inhibitory concentration 50 (IC50). Moreover, intestinal absorp-
tion studies and blood levels in vivo revealed a 13-fold increase in 
relative oral bioavailability of the drug formulated in the aerogels 
compared to that of a commercially available formulation (Taxol). Real- 
time imaging evaluation of biodistribution of paclitaxel and antitumor 
efficacy in MCF7 subcutaneous xenografts confirmed the benefits of 
paclitaxel formulation in the oral aerogels compared to intravenous 
administration of the marketed formulation [121]. 
Aerogels prepared with halloysite nanoclay (HNT) have also showed 
capability to sustain the release of ibuprofen and dexamethasone at both 
gastric and intestinal pH, with slightly slower release rate at acidic pH 
[122]. First, HNT were loaded by soaking in ibuprofen solution and 
underwent polymerization and crosslinking with phenyl vinyl silicone 
oil to obtain microspheres that were finally loaded with dexamethasone 
also by soaking. The dually loaded HNT aerogels had specific surface 
area in the 176–138 m2/g range with predominance of mesopores, 
sustained the release of both drugs for 48 h (Table 2, entry 18) and 
exhibited good compatibility with intestinal epithelial cells [122]. 
Dually temperature- and pH-responsive aerogels have been prepared 
using alginate grafted with PNIPAM (temperature-responsive block) and 
poly(N-hydroxymethylacrylamide) (PNHMAM, hydrophilic block). 
Indomethacin was added to the copolymer solution and then, the gels 
were freeze-dried [123]. Drug release was investigated at pH 2.1 and 7.4 
and at 25 and 42 ◦C. Indomethacin release occurred faster at pH 7.4 
according to the drug pH-dependent solubility profile (Table 2, entry 
19). An increase in temperature from 25 to 42 ◦C notably accelerated 
further the release rate due to a squeezing effect as the aerogel network 
shrinks (Fig. 13). Other authors reported on temperature-sensitive aer-
ogels from other sources such as cellulose and its derivatives [67,124]. 
Heat-denatured protein aerogels have demonstrated higher stability 
against disintegration in gastric and intestinal media compared to silica 
and polysaccharide aerogels. Whey protein, egg white protein or sodium 
caseinate have been shown suitable to prepare aerogels by solvent ex-
change and scCO2 drying. Whey protein aerogels loaded with ketoprofen 
by supercritical impregnation showed a controlled and pH-dependent 
drug release at pH 1.2 and pH 6.8. Interestingly, the pH conditions 
used in the gelation process largely influenced the ketoprofen release 
profiles [125] (Table 2, entry 20). Protein aerogels supercritically 
impregnated with fish oil were subjected to digestion mimicking saliva, 
gastric and intestinal environments. Whey protein and sodium caseinate 
aerogels released the oil selectively in the intestinal environment 
(Table 2, entry 21). Egg white protein aerogels showed incomplete 
release due to an excessive resistance against enzymatic degradation 
[126]. Although not tested yet, the resistance to peptide digestion and 
the intestine-selective release of these heat-denatured proteins may 
open novel ways for the delivery of labile therapeutic molecules, such as 
peptides and proteins. 
3.3. Coated and core-shell aerogels 
As described above, non-functionalized silica aerogels commonly 
display immediate release because of the adsorption of the drug in the 
amorphous state on a skeleton that exposes an extraordinarily large 
surface area in contact with the physiological fluids. In addition to 
functionalization with hydrophobic moieties, coating of aerogels and 
preparation of core-shell architectures is being intensively investigated 
to regulate drug release. For instance, aerogel-hydrogel composite 
structures have been proposed to regulate ketoprofen release from silica 
aerogels [127]. The photoinitiator eosin was added to the alcogels 
during aging. Then, the alcogels underwent supercritical drying, 
optionally hydrophobic modification, and finally supercritical impreg-
nation of ketoprofen. Hydrophilic and hydrophobic silica aerogels were 
coated with poly(ethylene glycol) (PEG) hydrogel via surface-initiated 
photopolymerization of the diacrylate monomer (MW 575 Da). Hydro-
philic aerogels coated with thick PEG layers prolonged drug release in 
0.1 N HCl medium for several days in a similar way as the non-coated 
hydrophobic aerogels. Ketoprofen diffusion coefficients were calcu-
lated to be 13.8⋅10− 6, 9.82⋅10− 6, 1.84⋅10− 6, 4.03⋅10− 6, and 0.32⋅10− 6 
cm2/min when delivered from hydrophilic, mid hydrophobic (66o water 
contact angle), strong hydrophobic (128o), PEG (15%)-coated hydro-
philic and PEG (30%)-coated hydrophilic aerogels, respectively. 
The interest in coatings to regulate drug release has also been 
explored for hybrid silica/alginate aerogels. The aerogels (900 m2/g; 
282 μm particle size) were prepared using an emulsification-internal 
setting protocol. Three different coatings were tested: alginate- 
hydroxypropyl methylcellulose (HPMC), silica-HPMC, and hydropho-
bic silica [128]. The beads (as hydrogels or alcogels) were dispersed in 
the coating aqueous solution and then mixed with an oily phase to 
obtain a water-in-oil emulsion (Fig. 14A). After aging, the coated hybrid 
beads were recovered, solvent exchanged and loaded with ketoprofen 
using supercritical processing. Interestingly, the presence of HPMC in 
the coatings notably enhanced drug deposition from 0.024 g/g in un-
coated aerogels to 0.104 g/g in alginate-HPMC and 0.076 g/g in silica- 
HPMC coated ones. Aerogels with hydrophobic silica coating had a drug 
content of 0.045 g/g (4.5 wt%). Release tests carried out at pH 1.2 
Fig. 13. (A) Indomethacin release profile from aerogels of alginate grafted with P(NIPAM-co-NHMAM) blocks recorded in buffer pH 7.4 at 25 and 42 ◦C and (B) 
sketch depicting the shrinking of the aerogels with the increase in temperature. Reprinted from Shao et al. [123] with permission from Elsevier. 
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indicated a very fast drug release from the uncoated hybrid aerogels (as 
expected) and slower release rate from the coated counterparts, partic-
ularly those coated with hydrophobic silica or silica/HPMC mixture 
(Fig. 14B). These latter coatings were more stable against disintegration 
in the acid medium. Nevertheless, the drug was still released faster than 
the dissolution rate of the unprocessed crystalline drug. 
The effects of Eudragit® L (Pharma-grade copolymer of methacrylic 
acid and ethyl acrylate) coating on ibuprofen-loaded silica aerogels 
(1100 m2/g; 200 μm-2 mm particle size) were investigated to obtain 
enteric formulations [21]. The content in supercritically adsorbed 
ibuprofen was 29 wt%. The loaded silica aerogels were first surface 
coated in a spouted bed with molten PEG2000 to protect the particles 
from the aqueous suspension of Eudragit® L also containing plasticizers. 
Direct exposition of the aerogels to the Eudragit® L suspension was 
shown to shrink the aerogels destroying the porous structure. Release 
tests carried out in 0.1 M HCl revealed that less than 20% of the loaded 
drug was released in 2 h (Fig. 15). The change to PBS pH 7.2 medium 
triggered the complete release of ibuprofen in less than 10 min. 
Although ibuprofen solubility is pH-dependent, the coating further 
contributed to prevent drug release at acidic pH. Moreover, a similar 
coating technology with Eudragit® L 30 D-55 applied to alginate-starch 
aerogels demonstrated the usefulness of the coating to preserve the 
aerogel structure during storage in environments of high relative hu-
midity [129]. Overall, these results showed the feasibility of adapting a 
coating technology well-established in the pharmaceutical industry to 
the processing of drug-loaded aerogels. 
Coating of triflusal-loaded silica and magnetite-silica aerogel parti-
cles with Eudragit® RL 100 has been also tested by using compressed 
CO2-induced polymer precipitation. The aerogel particles were 
dispersed in a Eudragit® RL 100 solution in an organic solvent. The 
addition of CO2 decreased the polymer solubility and provoked the 
precipitation on the surface of the particles, forming aggregates of aer-
ogel nanoparticles. The coating notably improved drug stability during 
storage and provided sustained release for several hours in acidic 
medium (HCl) [130]. 
Recently, enzyme-responsive hybrid aerogels have been designed for 
selective drug release at colon. Silica aerogels were soaked in 5-fluoro-
uracil solution and coated with dextran previous activation with 
glutaraldehyde of silica particles. Alternatively, the drug-loaded silica 
particles were directly coated with dextran aldehyde. The drug was in 
crystalline form and the uncoated aerogels released 78.4% and 86.4% 
after 4 h in simulated gastric and intestinal fluids in the absence of en-
zymes. The coatings slowed down the release to 1.3% and 3.5% released 
in the same time frame. Differently, in a release medium mimicking 
colon tumor environment (2 U dextranase/mL in acetate buffer pH 5.5) 
the aerogels coated with dextran or with dextran aldehyde increased the 
drug released to 24% and 13.4%, respectively. No changes were 
observed for non-coated silica aerogels. Relevantly, the coated aerogels 
without 5-fluorouracil were not toxic for Caco-2 cells, but once loaded 
with the drug the viability of these tumor cells decreased significantly, 
indicating the cytotoxic effect of the anticancer drug [131]. 
The multi-steps and long time processing involved in the coatings 
could be notably simplified by combination of co-axial prilling and su-
percritical drying. Co-axial prilling allows preparing core-shell or 
multilayered microgels in one step, with drugs in different layers. Sub-
sequent drying with scCO2 has been demonstrated to be a robust pro-
cedure to prepare core-shell aerogels with capability to regulate drug 
release profiles [132]. 
4. Aerogels for topical and transdermal administration 
Delivery of drugs to and through the skin has traditionally been a 
subject of attention because of the inherent advantages of topical and 
transdermal routes to treat local and systemic diseases. Direct topical 
drug administration to the skin has the benefits of allowing for local 
treatment of pathologies that are not easily addressed through a sys-
temic route, e.g., inflammation, bacteria and fungi infections and certain 
skin tumors. Drug administration through the skin (transdermal 
Fig. 14. (A) Scheme of the protocol followed to coat the hybrid beads before forming the aerogels, and (B) ketoprofen release profiles at pH 1.2 from the coated 
hybrid aerogels. Reprinted from Bugnone et al. [128] with permission of Elsevier. 
Fig. 15. (A) Scheme of the protocol followed to prepare silica aerogels and subsequent coating with stimuli-responsive polymers in a spouted bed, and (B) release 
profiles of ibuprofen from silica aerogels and Eudragit L-coated silica aerogels when placed in 0.1 M HCl (pH 1.0) or phosphate buffer pH 7.2 at 37 ◦C. Reprinted from 
Alnaief et al. [21] with permission from Elsevier. 
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delivery) has the advantage of avoiding liver first-pass metabolism, 
increasing systemic drug bioavailability, by using dosage forms that can 
be conveniently designed for prolonged delivery. Transdermal formu-
lations combine the maintenance of drugs levels in blood without fluc-
tuations and an excellent patient compliance. In addition, the treatment 
can be interrupted at any time. The main challenge for skin and trans-
dermal formulations is the overcoming of the epithelium barrier (espe-
cially of the dense stratum corneum), which restricts these routes to 
potent small-molecule drugs. Gels are been positioned as excellent 
platforms to address some of these limitations thanks to the design of an 
ample variety of hydrogels, organogels, emulgels and more recently 
aerogels [133]. 
In a pioneering study, silica aerogels loaded with dithranol demon-
strated enhanced drug penetration into human stratum corneum [25]. 
Dithranol is used in the management of psoriasis but requires discon-
tinuous application to avoid skin discoloration and it is quite unstable. 
Therefore, an optimal formulation should provide fast therapeutic levels 
in deep epidermal regions. The silica aerogels were supercritically 
impregnated with dithranol (5 wt%) and then, dispersed in hydrophilic, 
lipophilic and PEG ointments. Free drug was similarly dispersed and the 
final drug concentration in the formulations varied between 0.5 and 1 wt 
%. First screening of drug permeability was carried out by using artificial 
membranes that mimic the stratum corneum (dodecanol collodion 
membrane and Nephrophan® membrane). Although crystalline dithra-
nol is soluble in a lipophilic ointment, the addition of water or drug 
formulation into a hydrophilic ointment notably accelerated drug 
release from the silica aerogels due to the combined effect of the drug 
being in the amorphous state and the disintegration of the aerogel. 
Similarly, the highest permeability across the skin-mimicking mem-
branes was also recorded for dithranol-loaded aerogels dispersed in the 
hydrophilic ointment. Compared to the standard formulation of 
dithranol in soft paraffin, dithranol-loaded aerogels dispersed in the 
hydrophilic ointment provided higher flux (0.61 vs 0.49 g/(m2⋅h)) once 
applied on stratum corneum (Fig. 16) [25]. 
Strong research has been focused on development of antimicrobial 
aerogels [134]. Silica aerogels loaded with the hydrophobic antifungal 
fluconazole have been formulated in a sandwich-like multi-layer 
formulation, placing the aerogel particles in between a layer of poly 
(vinyl alcohol) (PVA) nanofibers and a PVA film [135]. PVA nanofibers 
containing the drug freely dispersed released the entire cargo within a 
few minutes [136]. Hydrophilic and hydrophobic silica aerogels loaded 
by soaking in a fluconazole solution in ethanol released the drug more 
controllably, according to a Fickian diffusion, but faster than the 
dissolution recorded for the non-processed crystalline drug. The multi- 
layer formulation provided structural support to the aerogel particles 
(PVA film) and a membrane (PVA nanofibers) to regulate the access of 
the release medium to the aerogels and the diffusion of the drug out. The 
drug-loaded silica aerogel particles that released more than 80% of the 
cargo in the first hour in contact with PBS, whereas the multi-layer 
composite sustained the release for more than 6 h following a non- 
Fickian mechanism (n =0.62–0.66) with the PVA swelling contrib-
uting to the control of drug release [135]. Relevantly, the antifungal 
activity against Candida albicans was preserved. 
Chitosan aerogels functionalized with methacrylic acid and itaconic 
acid and prepared via supercritical drying were designed for pH- 
dependent release of thymol for antimicrobial topical application 
[137]. The aerogels were impregnated with thymol (up to 4.6 wt%) 
using scCO2 and showed a high degree of swelling in aqueous medium, 
but the release profiles were not recorded. 
Nanofibers endowed with the features of aerogels have also been 
tested regarding antimicrobial therapy. Nanofibers of methoxy PEG- 
polycaprolactone block copolymer (mPEG-PCL) were prepared via 
electrospinning of aqueous solutions followed by freeze-drying and 
crosslinking [138]. The aerogel fibers (230 m2/g surface area; porosity 
>85%) behaved as water superabsorbents (25 g/g) and retained the 
mechanical properties and water sorption after 10 compression cycles. 
The fibers can be added with antimicrobial agents to be efficient against 
Gram-negative and Gram-positive bacteria in the treatment of skin 
wounds. 
Composite aerogels made of graphene oxide and PVA have been 
designed to host hemostatic agents and to sorb water and blood without 
disintegration [139]. Pais grape extracts of seed and skin rich in 
proantocyanidins were mixed with graphene oxide and PVA and then 
freeze-dried. The composite aerogels sustained the release of the extract 
components for several hours and significantly shortened the coagula-
tion time. The negative surface charge of graphene oxide contributed to 
the accumulation of blood cells on the surface of the aerogel and the 
Fig. 16. Percentage of dithranol that permeated through stratum corneum 
towards the receptor chamber when applied as suspension in soft paraffin 
(black squares) and as drug-loaded silica aerogels dispersed in a hydrophilic 
ointment (open triangles). Reprinted from Guenther et al. [25] with permission 
from Elsevier. 
Fig. 17. Composite aerogels prepared by mixing graphene oxide, poly(vinyl 
alcohol) and extracts from Pais grape and obtained via freeze-drying showed 
rapid sorption of blood and short coagulation time. Reprinted with permission 
from Mellado et al. [139]. Copyright (2018) American Chemical Society. 
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stimulation of platelets, showing thrombogenic activity (Fig. 17). 
Similarly, hybrid composites of silica nanoparticles dispersed in hyper-
branched networks of PVA and poly(acrylic acid) (PAA) and trans-
formed into aerogels by freeze-drying, have been shown suitable to 
sustain the release of hydrophobic drugs. The aerogels showed excellent 
compatibility with fibroblasts, and increasing the PAA/PVA ratio, the 
release rate of dexamethasone was slower. Moreover, silica nano-
particles could be decorated with ammonium groups to exhibit bacte-
ricidal activity against common skin pathogens [140]. 
5. Aerogels for pulmonary and nasal administration 
Most of the therapeutic proteins processed as inhalation powders and 
a growing percentage of the drug-loaded carriers for pulmonary 
administration are already prepared by using supercritical fluids [50]. 
As outlined above, scCO2 allows the processing at near ambient tem-
perature, which is especially favorable for labile therapeutic molecules. 
Moreover, the feasibility of tuning sizes and compositions and the 
excellent aerodynamic properties of the obtained particles (either drug- 
loaded or carrier-free) have pointed out supercritical fluid particle 
design as a key tool for dry powder inhaler (DPI) formulations 
[141,142]. Moreover, vaccines based on immunogenic nanoparticles for 
mucosal (nasal) administration are already being developed using the 
supercritical fluid technology [143]. 
Aerogels still represent an incipient contribution to the field among 
the different particle types that can be obtained via the supercritical 
fluid technology for pulmonary and nasal delivery. So far, aerogels for 
pulmonary treatments can be classified in two groups: (i) aerogels 
intended for lung administration; and (ii) aerogels that sustainedly 
release volatile compounds to the air for subsequent inhalation. 
Hybrid aerogels made of mixtures of alginates and other poly-
saccharides attract attention for mucosal delivery. Aerogel microparti-
cles of alginate and low methoxyl pectin and kappa-carrageenan 
obtained via scCO2 drying showed high surface area (up to 548 m2/g) 
and mucoadhesive properties [144]. Ketoprofen was loaded via scCO2 
adsorption (17–22 wt%) and quercetin was loaded during solvent ex-
change and deposited via gas antisolvent precipitation (3.1–5.4 wt%). In 
both cases, the drugs were in the amorphous state on the aerogel skel-
eton, and the release was completed within less than 60 min in PBS pH 
6.8. To improve biodegradability in the lungs, hybrid alginate- 
hyaluronic acid aerogel microspheres with suitable aerodynamic 
diameter of 5 μm (446–611 m2/g surface area) were designed [27]. The 
aerogels were prepared via emulsion-gelation followed by scCO2 drying, 
conditioned in capsules (10 mg) to be inserted in a DPI device, and 
successfully evaluated in an Andersen Cascade Impactor internally 
coated to mimic the humidity of the airways. No data on drug release has 
been reported yet. 
The bronchodilator salbutamol sulfate has also been formulated in 
aerogels to be delivered to the lungs. Chitosan-based aerogels obtained 
via conventional dropping and ionic gelation in sodium tripolyphos-
phate (STPP) solution showed capability to prolong salbutamol release, 
but the aerodynamic properties were not evaluated [145]. Recently, 
aerogels with very precise particle size and very narrow particle size 
distribution have been obtained by combination of the inkjet printing 
and the supercritical fluid technologies (Fig. 18A). This 3D-printing 
technology was firstly applied to prepare microspheres of alginate by 
precise dropping of the polymer dispersion in a calcium chloride solu-
tion also containing salbutamol sulphate [26]. The aerogels had a drug 
content of ~3 wt%, in line with commercially available DPI formula-
tions, and showed sustained drug release in PBS pH 7.4 (Fig. 18B). As a 
proof-of-concept, the inkjet-printed aerogels (8 mg) were loaded in a 
capsule (size 3) and fitted to an impactor. The drug-loaded aerogels had 
4.0 ± 1.5 μm aerodynamic diameter and exhibited good flowability, 
with most drug retained in the stage corresponding to the bronchi and 
bronchioles regions [26]. 
Recently, alginate-chitosan aerogels have been tested as carriers of 
antitumor drug cisplatin for intratracheal administration [28]. The 
aerogel particles (0.4 μm) prepared by emulsion gelation (without using 
divalent salt ions) followed by scCO2 drying, were impregnated with the 
cytotoxic agent cisplatin crystalline particles under supercritical condi-
tions. The aerogels released 60% of the drug in 2 h in phosphate buffer 
pH 7.4 and sustained the release of the remaining amount for six more 
hours. In vivo tests were carried out dispersing the aerogel particles in a 
small volume of saline serum and administered near the bifurcation of 
the trachea. Acute toxicity tests revealed that the materials used to 
prepare the aerogels are non-toxic by themselves. Subacute repeated 
administration tests indicated that the cisplatin dose was better toler-
ated when encapsulated in the aerogels, decreasing untoward events and 
mortality compared to the treatment with the free drug. Further in vivo 
studies should be focused on evaluating the biodegradability of the 
aerogels in the lung and the optimization of the amount of the drug 
encapsulated [28,146]. 
Another material under investigation as carriers for lung delivery of 
small-molecule drugs and proteins is graphene aerogel, which has 
shown high encapsulation yield of the antioxidant protein catalase and 
sustained release [147], though their biocompatibility by this adminis-
tration route has not been demonstrated yet. 
Differently to the direct drug delivery to the lungs, aerogels may also 
be intended for the release of volatile compounds to the air from which 
the compounds can be inhaled for a variety of therapeutic purposes. This 
strategy avoids the contact of excipient components of the aerogels with 
the mucosa. For example, hydrophilic (0.105 g/cm3 bulk density) and 
hydrophobic (0.121 g/cm3 bulk density) silica aerogels have been 
evaluated for the temperature-induced release of 1-menthol and 2- 
methoxy pyrazine [148]. These volatile compounds were loaded in the 
aerogels via scCO2 impregnation. Both compounds are highly soluble in 
scCO2 but 1-menthol is solid at room temperature and 2-methoxy pyr-
azine is liquid, which implies that the later does not solidify in the pores. 
Unprocessed 1-menthol evaporated completely after 55 min at 60 ◦C, 
but once included in the hydrophilic aerogels (23.3 wt% load) the 
release started when temperature reached 200 ◦C and was completed at 
400 ◦C due to the strong hydrogen bonding with the silica skeleton. 
Release from hydrophobic aerogels (7.2 wt%) was triggered at 150 ◦C. In 
the case of 2-methoxy pyrazine (9.8 wt% load in hydrophilic and 3.3 wt 
Fig. 18. (A) Application of the inkjet printing technology to the preparation of monodisperse alginate beads that were loaded with salbutamol sulphate, solvent 
exchanged and dried using scCO2; and (B) Comparison of salbutamol sulphate release patterns from drug-loaded aerogels (open circles) and the unprocessed free 
drug solution (black squares). Reprinted from López-Iglesias et al. [26] with permission form Elsevier. 
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% in hydrophobic aerogels), fast release was recorded at 60 ◦C. Overall, 
the aerogels could be stored for several weeks at room temperature 
without loss of volatile compounds and should be moderately heated to 
trigger the release. Differently, aerogel microspheres from rice husk ash 
have shown remarkably large capability to adsorb eugenol (up to 8 g/g) 
and to release it to the air in a sustained way for 17 days at room tem-
perature without need of heating [57]. 
Starch aerogels chemically crosslinked with trisodium citrate were 
tested for the release of trans-2-hexenal, a volatile antifungal agent. The 
aerogels were loaded by soaking in an aqueous drug solution and then 
surface-coated with Span 80 by spray coating. Aerogel formulations 
strongly retarded the release of the trans-2-hexenal at room temperature 
with respect to the free compound (1 h vs. 6–8 h for 100% release). The 
surface coating of the aerogels also delayed the antifungal activity 
against Aspergilus parasiticus inoculated in pistachio nuts reaching total 
inactivation after 19 h, in comparison to the 14 h for the uncoated 
aerogel counterpart [149]. In a similar context, aerogels loaded with 
hexanal (inhibitor of phospholipase D activity and of myco-toxins syn-
thesis) were prepared by adding sunflower oil to galactoglucomannan 
and cellulose nanofibril hydrogel (cross-linked with ammonium zirco-
nium carbonate) followed by freeze-drying [150]. The aerogels showed 
sustained release of hexanal for several weeks lipid oxidation pathway, 
with a rate regulated by the lipid oxidation pathway of the sunflower oil. 
6. Emerging applications: gene therapy, theranostics and other 
biomedical applications 
Combination of aerogel performances with novel materials (e.g. 
chips) and technologies (e.g. additive manufacturing) may further 
expand the scope of applications of aerogels in the drug delivery field. 
Reports on aerogel-based implantable drug delivery systems for 
long-term release are still scarce. Biocompatibility of implants made of 
polyurea-crosslinked silica aerogels has been evaluated after subcu-
taneous and intramuscular implantation [151]. Preclinical evaluation 
through the monitoring of tissue damage, fibrosis and displacement of 
the implant for 20 months revealed that these aerogel-based implants 
can be considered as safe. No biodegradation was observed in vivo. Very 
relevantly, the implants inserted in the leg muscle did not move despite 
the absence of fixation (no suture) and unrestricted movement of the 
animal. This finding can be associated to the light weight (low density) 
typical of the aerogels. It should be noticed that the implants were 
manually shaped from monoliths, which may narrow the possibilities of 
fitting to the morphology demands of trocars used for the implantation 
and the tissue constrains. Additionally, a post-treatment with ethylene 
oxide was required to ensure sterility, which may be not compatible 
with some therapeutic substances. Advances in sterilization strategies 
that allow for aerogels processing and sterilization in one step may 
widen the therapeutic substances that can be included while shorten the 
processing time [19]. Interestingly, development of aerogel particles 
depots endowed with tumor-selective drug release was recently 
explored as coadjuvant therapy after tumor surgery or for the treatment 
of tumors that cannot be surgically resected [152]. Methotrexate was 
covalently conjugated to silica-gelatin aerogels through a labile bond 
that can be hydrolyzed by collagenases. In the absence of the enzyme the 
drug is not released. Differently, drug release rate is precisely regulated 
by the collagenase activity of the cells, which allows for differential drug 
accumulation in cancer and non-cancer cells. 
A step forward in the development of implantable medicines is to 
adapt additive manufacturing technologies to aerogel materials. 3D- 
printing technologies may allow obtaining dosage forms with patient- 
personalized drugs, doses, and release profiles and with ad-hoc archi-
tectures to facilitate the administration through different routes [153]. 
Feasibility of producing spherical particles by inkjet printing [26] or 
complex objects with customizable pore structure through 3D micro-
extrusion [154] has been demonstrated for silica and polysaccharide 
aerogels. In the case of 3D microextrusion of wet masses of cellulose 
nanocrystals, the aerogels were generated in a subsequent step involving 
freeze-drying. The obtained architectures showed physical properties 
suitable for the preparation of customizable scaffolds [154]. In the case 
of silica-based aerogels two different strategies have recently been 
explored for 3D printing: (i) 3D printing of silica alcogel precursor by 
irradiation of solutions of tetraethyl orthosilicate, diacrylates and pho-
toinitiator (laser-induced 3D printing) [37], and (ii) 3D extrusion of 
preformed silica aerogels in the presence of silica nanoparticles, fol-
lowed by gelling in ammonia atmosphere [10]. These two approaches 
are compatible with scCO2 drying of the printed objects while main-
taining excellent shape fidelity. The performances in the drug delivery 
field are still to be explored. 
In addition to drugs, aerogels can incorporate enzymes and metals 
which opens the possibility of their use in theranostics (therapy + di-
agnostics). Only recently, silica aerogels have been adapted to act as 
supports of a variety of enzymes (glucose oxidase, acid phosphatase and 
xylanase) while preserving both the enzyme activity and the aerogel 
structure [155], which will open a wide range of novel applications. In 
the case of metals, a metallic precursor can be supercritically deposited 
into the aerogel structure or, alternatively, the preformed aerogel can be 
soaked in the metallic precursor. The subsequent reduction (chemical or 
thermal) of the precursor generates the metal nanoparticles in situ 
[156]. Compared to other technique to produce metal nanoparticles, the 
supercritical deposition has the advantages of precise control of size, 
shape, and more homogeneous distribution of the particles [157,158]. 
Bimetallic nanoparticles have been shown to preserve their properties 
without risk of aggregation when dispersed into aerogels. Detailed 
protocols for the preparation of metallic nanoparticles-aerogel com-
posites have been recently revisited [159]. Bimetallic AuAg nano-
particles supported in aerogels have shown excellent performances for 
Surface Enhanced Raman Spectroscopy (SERS); the dispersion in aero-
gels remarkably improved the sensitiveness of a probe molecule [160]. 
Core-shell nanoparticles of Pd@Pt dispersed in PVA aerogel together 
with alcohol oxidase have been integrated in a portable (point-of-care) 
device for alcohol assay in saliva. Replacing the enzyme by glucose 
oxidase the same platform allows for quantification of glucose in blood 
[161]. 
Hybrid gold nanocrystals in graphene aerogels have demonstrated 
potential as sensors of circulating tumor DNA in human blood for patient 
stratification and monitoring of treatments [162]. If adapted to the 
sensing of specific biomarkers, the aerogels could be designed for 
feedback-regulated drug release. Combination of graphene and shape 
memory polymers has rendered aerogel frameworks that exhibit ultra-
fast response and large deformation under electrical stimulation, with 
potential for sensors and actuators [163]. Moreover, plasmonic metallic 
nanostructures can further expand the applications of aerogels in pho-
tothermal therapy. Irradiation of carbon aerogels with 808 nm laser has 
been shown suitable for ablation of osteosarcoma while serving as 
scaffold for bone regeneration [164]. This field is still very incipiently 
developed but a very appealing future can be predicted. 
Feasibility of using aerogels as non-viral vectors for gene therapy is 
also under evaluation. Polyethylenimine (PEI), one of the most investi-
gated condensing agents of gene material, can be grafted to cellulose 
nanofibril aerogels [165]. These biodegradable PEI-modified aerogels 
have shown high affinity for anionic drugs such as sodium salicylate, 
reaching loadings of 287 mg/g. Drug release was sensitive to both pH 
and temperature, being faster at pH 7.4 than pH 2.0 and at 37 ◦C than 
20 ◦C. The grafting of PEI to silica particles has also been implemented 
[166]. DNA itself exhibits high affinity for pristine silica aerogels [167] 
and both DNA and small-interference RNA (siRNA) can be included into 
the mesopores [168,169] mainly through hydrogen bonding between 
the phosphate groups of the genetic material and the Si-OH groups of the 
aerogel. Reinforcement of the interactions with PEI may notably 
improve the performance of aerogels in the gene therapy field. In par-
allel, the capability of aerogels to capture nucleotide acids can be 
exploited also as sensors. Silica aerogels prepared in the presence of 
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ionic liquids have been shown also to immobilize oligonucleotides for 
selective recognition of complementary DNA targets [170]. 
7. Scale-up and life cycle assessment 
The growing interest in aerogels and the wide range of applications 
in the pharmaceutical field lead to the need to hypothesize their 
manufacture on pilot and industrial scale. Indeed, despite the broad 
interest, aerogel production is generally treated considering the bench 
scale; however, some scientific papers on large-scale aerogel production 
have been published. It should also be considered that in the pharma-
ceutical field, aerogels are used for some applications in the form of 
microparticles of controlled size, and for some others as patches of 
known geometry. In the former case, continuous processes can be 
developed, whereas in the latter case the production of aerogels may 
require batch processes. 
In general, a common approach for the scale-up of a process relies on 
the use of similarities of the processes carried out on different scales by 
means of dimensionless numbers, which characterize the process. A 
process is correctly scaled on a pilot or industrial scale if (i) it takes place 
in a plant with larger dimensions but the same geometry as the bench- 
scale plant; (ii) the dimensionless numbers characteristic of a given 
process, evaluated on the pilot and industrial scale plants, have the same 
numerical value as the dimensionless numbers calculated for the bench- 
scale plant [171]. 
Some papers related to the production of alginate aerogel obtained 
by emulsion gelation on a pilot scale have been published. For example, 
sodium alginate aerogel particles have been prepared by emulsion 
gelation and dripping methods followed by supercritical drying at 
various scales [172]. In the case of the lab-scale plant, an apparatus with 
a volume of 0.25 L was used, whereas in the pilot-scale plant the volume 
of the vessel was 2 L. Alginate aerogel microparticles were also produced 
using emulsification setups with different dimensions: a batch setup 
producing an emulsification volume of 130 mL, a semi-continuous set- 
up with a 2 L funnel, and a continuous setup fed by a mixture of oil and 
alginate solution from two 20 L vessels [173]. When microparticles or 
microemulsions have to be treated, the atomization step is crucial, 
because it affects the final particle size; therefore, the scale-up is 
generally performed taking constant the Reynolds number (Re) and the 
Ohnesorge number (Oh). Re is the well-known ratio of inertial forces to 
viscous forces, as expressed in Eq. (4) 
Re =
Dvρ
μ (4)  
whereas Oh is the ratio between the viscous forces and the surface 





√ (5)  
where D is the nozzle diameter, ρ and μ are the density and viscosity of 
the fluid, v is the velocity and σ is the surface tension. 
Production of aerogels in the form of patches of a given geometry is 
intrinsically a batch process, and the process scale-up has been rarely 
performed. In these cases, quasi-continuous productions are developed 
considering two or three minibatches that operate alternately. The effect 
of the plant scale-up on the production of starch aerogel for drug de-
livery was studied from an environmental point of view [174]. Two 
different scales were considered for the supercritical drying: a bench- 
scale plant with a vessel volume equal to 0.5 L and a pilot scale plant 
with a vessel volume equal to 5.2 L. The environmental impacts on an 
industrial scale plant (vessel volume equal to 100 L) were also simu-
lated. In order to quantify the environmental impacts of the aerogel 
production process, demonstrating that the scale-up significantly re-
duces the emissions, the impacts related to the process conducted on the 
bench-scale and on the pilot-scale plant were compared through a life 
cycle assessment (LCA) analysis. LCA is a recognized tool used to 
quantify the environmental impact of a product or a process throughout 
its life cycle, identifying the steps of the process that are critical from the 
environmental point of view. The chosen functional unit used to 
compare, from the environmental point of view, the production of starch 
aerogel at different scales was equal to 1 g of aerogel. The analysis 
allowed comparing the process conducted on different scales using, 
according to the IMPACT 2002+ method [174], fifteen midpoint in-
dicators or four damage categories: human health, ecosystem quality, 
climate change and resources (Fig. 19). 
Comparing the environmental impact related to the different damage 
categories, the scale-up from the bench-scale to the pilot-scale implied a 
reduction of the impact equal to 68% considering the human health, 
72% considering both ecosystem quality and climate change and 74% 
considering the resources. From the simulation on the industrial scale 
plant, it is possible to hypothesize a reduction of the impact equal to 
96% considering the ecosystem quality and to 95% considering human 
health, climate change and the resources. 
More recently, the LCA of the impregnation of starch aerogel with 
alpha-tocopherol was performed considering the processing on indus-
trial scale [175]. Two different scCO2 based processes were considered. 
First, the supercritical drying in a 100 L vessel was used to obtain the 
starch aerogel from the alcogel, then vitamin E (alpha-tocopherol) was 
impregnated into the aerogel using a 20 L internal volume plant. All the 
emissions were reported to the chosen functional unit, which was a 120 
mg starch aerogel tablet containing 15 mg of alpha-tocopherol (daily 
therapeutic dose). 
The performed analysis showed that the stages most affecting the 
environmental categories were the agricultural stages, the supercritical 
drying to obtain the aerogel, and the supercritical impregnation. Some 
scenarios were proposed to minimize the impacts of these steps, which 
included the possibility of recycling part of the ethanol (used in the 
hydrogel-to-alcogel step) and of reducing the consumption due to the 
CO2 condensation. 
8. Conclusions and future perspectives 
The unique features of aerogels open new avenues to address rele-
vant drug formulation challenges and to design advanced drug delivery 
systems with novel performances. Poor drug solubility can be overcome 
by deposition on the aerogel skeleton of large amounts of drug in the 
amorphous state. The large surface area with an enormous inter-
connected pore network facilitates the contact with the aqueous milieu 
and the diffusion of the dissolved drug. Alternatively, the drug release 
patterns can be regulated through a variety of options like the combi-
nation of swellable/erodible skeleton components, the tuning of the 
intensity of the drug/skeleton interactions, the coating with membrane- 
like substances and the integration of stimuli-responsive components. 
Moreover, the large surface area, low density, and capability to uptake 
liquids, which are genuine properties of aerogels, expedite the direct 
application of aerogels through a variety of mucosal administration 
routes, particularly oral, pulmonary, nasal and topical. Current pro-
tocols to manufacture aerogels already allow the use of almost any 
organic or inorganic material as skeleton component and can be adapted 
to formulate drugs with quite different physicochemical features and 
stability. Versatility is also extensive to the final sizes and formats of 
aerogel formulations. Relevantly, so far toxicological studies pointed out 
aerogels as quite safe [176,177], but further in vivo studies are still 
required. 
Analysis of the literature on aerogel production clearly shows that 
most of the published articles are related to bench-scale production. The 
growing interest in the application of aerogels in the pharmaceutical 
field prompts experimentation on a pilot scale as a first step towards 
aerogels’ production at the industrial scale. Large-scale (industrial) 
production of aerogels also needs considering the environmental aspects 
related to the production itself. LCA analysis enables the quantification 
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of specific impacts of the various production stages involved to identify 
the most impacting phases and propose strategies to minimize their 
impact. 
Considering the interest in the use of aerogels in the pharmaceutical 
field and provided that the operating conditions can be optimized from 
the point of view of minimizing the environmental impact of the pro-
cesses, these materials seem ready to be produced on an industrial scale. 
Next steps should focus on how drug-loaded aerogels can be transformed 
into true medicines. Namely, the possibilities of obtaining tablets, cap-
sules, ointments, inhalation powders or injectable formulations, among 
others, while preserving the unique properties of aerogels are still to be 
explored. 
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M. Koebel, F. Liebner, M. Neagu, I. Smirnova, An opinion paper on aerogels for 
biomedical and environmental applications, Molecules 24 (2019) 1815. 
[15] H. Paukkonen, M. Kunnari, P. Lauren, T. Hakkarainen, V.V. Auvinen, T. Oksanen, 
R. Koivuniemi, M. Yliperttula, T. Laaksonen, Nanofibrillar cellulose hydrogels 
and reconstructed hydrogels as matrices for controlled drug release, Int. J. Pharm. 
532 (2017) 269–280. 
[16] A. Soleimani Dorcheh, M.H. Abbasi, Silica aerogel; synthesis, properties and 
characterization, J. Mater. Process. Technol. 199 (2008) 10–26. 
[17] C. Vakifahmetoglu, D. Zeydanli, V.C. Ozalp, B.A. Borsa, G.D. Soraru, 
Hierarchically porous polymer derived ceramics: A promising platform for 
multidrug delivery systems. Mater, Design 140 (2018) 37–44. 
[18] I. Pasquali, R. Bettini, Are pharmaceutics really going supercritical, Int. J.Pharm. 
364 (2008) 176–187. 
[19] N. Ribeiro, G.C. Soares, V. Santos-Rosales, A. Concheiro, C. Alvarez-Lorenzo, C. 
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C.A. García-González et al.                                                                                                                                                                                                                   
Journal of Controlled Release 332 (2021) 40–63
63
[145] R.M. Obaidat, B.M. Tashtoush, M.F. Bayan, R.T. Al Bustami, M. Alnaief, Drying 
using supercritical fluid technology as a potential method for preparation of 
chitosan aerogel microparticles, AAPS PharmSciTech 16 (2015) 1235–1244. 
[146] M. Alnaief, R.M. Obaidat, M.M. Alsmadi, Preparation of hybrid alginate-chitosan 
aerogel as potential carriers for pulmonary drug delivery, Polymers 12 (2020) 
2223. 
[147] Y.Q. Li, K. Liao, S. Lee, A comparative study of antioxidant-loaded carbon 
nanoparticles as drug delivery vehicles, RSC Adv. 4 (2014) 56992–56997. 
[148] B.S.K. Gorle, I. Smirnova, M.A. McHugh, Adsorption and thermal release of highly 
volatile compounds in silica aerogels, J. Supercrit. Fluids 48 (2009) 85–92. 
[149] N. Abhari, A. Madadlou, A. Dini, Structure of starch aerogel as affected by 
crosslinking and feasibility assessment of the aerogel for an anti-fungal volatile 
release, Food Chem. 221 (2017) 147–152. 
[150] M. Lehtonen, S. Kekäläinen, I. Nikkilä, P. Kilpeläinen, M. Tenkanen, K. 
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